CONTROL OF MEMBRANE TRAFFIC

Abstract: The present invention relates to the control of membrane traffic inside cells, such as those involving fusion events and in particular those involving exocytic events. It more particularly relates to N-terminal fragments of TeNT-insentive VAMP, and to TeNT-insentive VAMP deleted from such fragments, and to the biological applications of such products, notably for controlling TeNT-resistant pathways such as neurite outgrowth and cell motility.

Description: CONTROL OF MEMBRANE TRAFFIC The present ιn\entιon relates to me control ot membrane traffic inside cells such as those involving fusion events and in particulai those involving exocvtic events It more particularlv relates to the positive and negative regulation ot anv tetanus neuroto\ιn (Te\T) -resistant pathwav inside a cell such as anv pathwav involving the activitv of a AMP ( vesicular-associated membrane protein) The present invention indeed provides with new products and new means for controlling such a membrane traffic inside a cell, and notabh or controlling an cell activitv involving a TeNT-insensitive VAMP such as TI-VΛMP (tetanus neurotoxm-insensitive vesicle-associated membrane protein) Mam different VAMP have been descπbed in the prior art These VAMP are receptors expressed bv cell vesicles, and are known to be involved in exocytic events But verv little was known on how to control the activitv of TeNT- msensitive VAMP, and of TI-VAMP in particular The present invention provides with new products and means solving this problem, and further gives for the first time the demonstration that such new products and means are efficient in controlling membrane traffic in non- epithelial cells, and notablv in neuronal cells and in tumor cells The present invention thus encompasses anv isolated polvpeptide . the sequence of which corresponds to a sequence selected from the group consisting of the domain sequences of TeNT-insensitive VAMP such as TI-VAMP. and the conservative fragments and variants thereof Such isolated polypeptides do not comprise any coiled coil motif It more particular!} relates to anv isolated polvpeptide . the sequence of which corresponds to a sequence selected from the group consisting of a sequence corresponding to SEQ ID N c 2. a sequence corresponding to SEQ ID N°20. the sequences corresponding to anv conservative fragment of SEQ ID \°2. the sequence-, corresponding io anv conservative fragment of SFC) ID \ = 2ϋ the sequences corresponding to anv conservative variant of SEQ ID N c 2. the sequences corresponding to anv conservative variant of SEQ ID c 20 These polypeptides will be referred to herein as tne \ter polv peptides SEQ ID \ = 2 refers to an isolated polvpeptide tne sequence of which corresponds to the first 120 amino acids (\l'-\ ι: in Figure 8) of human normal TI- AMP (SEQ ID V6) SEQ ID V2 is also referred to as \ter in the below examples SEQ ID V20 refers to an isolated polvpeptide the sequence of which corresponds to the first 101 am o acids (M'-A 1 on Figure 8) of human normal TI-VAMP (SEQ ID N°6) As these aa sequences, their corresponding polvnucleotidic sequences, and the conservative fragment sequences thereof are from normal human origin, they and their human variants are considered as corresponding to one of the best modes of the invention Whereas the complete sequence of TI-VAMP has been previouslv descπbed N-terminal domain . e \-terminal region which excludes anv coiled coil motif) had no known function up to the present invention As there was no aim at it the skilled person would then not have seriously encompassed to produce a polvpeptide limited to such a \-terminal domain, or to produce a polvpeptide limited to the coiled coils plus C-terminal region of TI-VAMP The present invention describes for the first time a biological function for these polypeptides thev are capable of regulating a membrane traffic, and in particular TeNT-resistant pathways According to a further remarkable aspect, thev are capable of exerting these capacities on neuronal maturation and/or differentiation (neuπte outgrowth) and on the moti ty of tumor cells Bv « conservative » product (polypeptide or pol nucleotidic fragment variant polvpeptide or polynucleotide) it is meant in the present application that this product is capable of showing under physiological conditions at least one of the biological properties shown bv a « parent » product (SEQ ID \ τ °2 -also referred to as \ter in the below examples - and SEQ ID \°20 -from M to A 1 0 ' on figure S) Such biological properties notably include the capacity of inhibiting a membrane traffic pathw ay inside a cell the capacπv of inhibiting a function inv olv ing at least one e pathw av the capacity of inhibiting the activ ity ot a Te T-msensιtιv e VAMP such as 1 1-0 AMP the capacity of inhibiting a function inv olv ing a fusion function or an exocy tose function ot a cell, a capacity of inhibiting neuπte outgrow th a capacity of inhibiting the motihty of cells such as metastasis-forming cells ( tumor cells) Any cell enabling the skilled person to perform the desired assay is appropπate Preferred cells are cells of animal or human origin, including cell lines Cells of special interest for industrial applications namely include neuronal cells and tumor cells, from primary cultures, as w ell as from cell lines such a PC 12 cells for neuronal cells, or MDCK, HeLAa. CACO-2. NIH-3-T3 cells for tumor cells By phy siological conditions it is herein meant in \ ι\ o conditions, or in vitro conditions mimicking the in \ ιvo ones ty pically appropπate phy siological conditions comprise conditions ol medium composition, atmosphere. pH which are adequate to the cells that may be involv ed in the assay , and notably to animal or human cells By a « variant » product, it is herein meant any product which corresponds to the « parent » product after one or several of its elementary components (ammoacid. or w hen the case arises, nucleotide has (have) been deleted and/or inverted and/or substituted, in so far this ariant product has retained at least one of the biological properties shown by the « parent » product as abov e-defined W hen reference is made to any amino acid or polypeptide deletion inv ersion substitution it has to be considered in the context of the universal genetic code and its redundancies A v ariant product thus notably encompasses any product . the sequence ot w hich show s w ith the parent product ( SEQ ID V2 or V20 in the case of Dolv peotides SEQ ID V I or SEQ ID 19 tor their respective DNA sequences) over the entire length of this parent product sequence, an homology of at least about 50V particularly of at least about 60° o. more particularlv of at least about 70° o. preferably of at least about 80° o more preferably of at least about 90° o the most preferred being ot at least about 95° o A variant product also encompasses anv conservative fragments of such products While the invention is more particularly illustrated for human cells variant products which can be found in other cell types or in other species and notabh among animals are thus encompassed by the present in ention Bv "TeVF-resistant" or "TeNT-insensitive pathway or receptor the present application means that said pathway or said receptor is still active when the cell wherein said pathway takes places or said receptor is expressed is placed into contact with tetanus neurotoxm under exposure to the TeNT produced by the clostπdium tetanπ in the case of sensitive cells such as neurons, or of transfection ofthe cD A coding for the light chain of TeNT in all cases In the present application the expressions ' inhibiting' "stimulating" are meant as statistically significant negative or positive difference and thus encompasses "blocking" and. respectively inducing According to a complementary and corresponding aspect, the invention also relates to any isolated polypeptide . the sequence of which corresponds to a sequence selected from the group consisting ofthe TeNT-msensitive VAMP sequences, such as TI-VAMP sequence, deleted from their respective N- terminal domains, provided that the resulting "deleted" polypeptide is still capable of showing an activity ofthe coiled coil type (i e the SNARE motif activity is not disrupted) namely is still capable of binding to at least one of the target SNARE (target Soluble Vethvlmaleide-sensitive fusion protein Attachment Receptor) ofthe corresponding complete VAMP (t-SNARE of TI- VAMP namely comprise SNAP 25. SNAP23. syntaxml. syntaxm3) Coiled coils of VAMP can be predicted by computer programs such as COILS These polvpeptides will be referred to herein as the < deleted » polypeptides (also referred to as ΛNter-TI-V AMP in the below examples ) The inv ention more particularly relates to poly peptides the sequence of w hich corresponds to SEQ ID V6 of w hich N-terminal domain has been deleted from at least one Nter poly peptide according to the inv ention Examples of such " "deleted poly peptides " include those . the sequence ot w hich corresponds to a sequence selected from the group consisting of SEQ ID V4 the sequences corresponding to any conservativ e v ariant of SEQ ID V4. and the sequences corresponding to any conser ativ e fragment of SEQ ID N°4 SEQ ID V6 refers to the complete amino acid sequence of human TI-\ AMP ( see figure 8) SEQ ID N°4 refers to the amino acid sequence ot an isolated poly peptide . the sequence of which corresponds to the amino acid sequence of human TI- VAMP deleted from the first 101 N-terminal amino acids ( e it corresponds to M 102 to the end of SEQ ID N°6) As SEQ ID N°4. its corresponding polv nucleotidic sequence (SEQ ID N°3 ). and the conservativ e fragments thereof are from normal human origin, they and their human v ariants are considered as one of the best modes of the inv ention The biological properties show n by a poly peptide of SEQ ID N°4 correspond to rev ersed properties of SEQ ID N°2 or 20 They notably include the capacity of stimulating a membrane traffic pathw av inside a cell, the capacity of stimulating a function involving at least one TeNT-resistant pathw ay , the capacity of stimulating the activ ity of a TeNT-insensitive VAMP such as TI- VAMP, the capacity of stimulating a function inv olv ing a fusion function or an exoc tose function of a cell, a capacity of stimulating neuπte outgrowth, a capacity of stimulating the motility of cells such as metastasis-forming cells « v ariant » is as above-defined Both the Nter and the "deleted" polypeptides of the invention are advantageously associated to any product enabling their passage inside a cell, such as an animal cell, a human cell a plant cell an eucary otic cell a protiste So as to make it penetrate into a cell a poly peptide ot the inv ention can be e g chemically modified, for examples by esteπfication by addition ot a pidi tail, and or can be associated to a carπer-deliv ery system such as liposomes The invention further provides with products derived from the Nter polypeptides ot the invention It thus relates to any product selected from the group consisting of the monoclonal antibodies capable of binding to a polypeptide according to the invention, and the Fab F(ab h CDR fragments thereof These products will be referred to as the 'binding" products ofthe invention Production of monoclonal antibodies is of common knowledge to the skilled person (notably Kohler and Milstein procedure) Such monoclonal antibodies advantageously do not bind to a « deleted » polypeptide of the invention The invention more particularly encompasses those products which are capable of inhibiting under physiological conditions at least one f the biological properties a Nter polypeptide according to the invention can show Such biological properties of a Nter polypeptide namely comprise the inhibition ofthe formation of complexes between a TeNT-insensitive VAMP such as TI-VAMP. and a target SNARE (e ς SNAP25. SNAP23 svntaxml. syntaxm3 for TI-VAMP) According to further aspect ofthe invention, sharing corresponding features with the polypeptides ofthe invention, there are provided pohnucleotides the sequence of which codes for the Nter polypeptides according to the invention, pohnucleotides . the sequence of which codes for the "deleted" polypeptides according to the invention, and pohnucleotides . the sequence of which codes tor any binding product according to the invention As Nter poh nucleotides. the invention more particularly relates to any isolated polynucleotide . the sequence of which corresponds to a sequence chosen . the sequence of which corresponds to a sequence selected from the group consisting of a sequence corresponding to SEQ ID V I . a sequence corresponding to SEQ ID V 19. the sequence corresponding to anv conserv ative fragment of SEQ ID V I . the sequence corresponding to anv conserv ativ e variant of SEQ ID V I . the sequence corresponding to any conservati e fragment of SEQ ID V I 9. the sequence corresponding to any conservative variant of SEQ ID I 9. SEQ ID V I refers to the DNA sequence coding for SEQ ID V2 (first N- terminal 120 aa of TI-VAMP. i. e from M 1 to N 12υ . that is to say from position 73 to position 432 on the TI-VAMP DNA Sequence, see figure 8). SEQ ID V I 9 refers to the DNA sequence coding for SEQ ID N°20 (first N- terminal 101 aa of TI-VAMP. i. e. from M 1 to position 101. that is to say from position 73 to position 375 on the TI-VAMP DNA sequence, see figure 8). As "deleted" poh nucleotides. the invention more particularly relates to any isolated polynucleotide . the sequence of w hich corresponds to a sequence selected from the group consisting of the SEQ ID V5 sequences of which 5 ' domain has been deleted from at least one Nter polynucleotide according to the invention. The "deleted" polvnucleotides of the invention namely comprise any isolated polynucleotide . the sequence of which corresponds to a sequence selected from the group consisting of a sequence corresponding to SEQ ID V3. the sequences corresponding to any conservative fragment of SEQ ID N°3. the sequences corresponding to any conservative variant of SEQ ID V3. SEQ ID V5 refers to the complete DNA sequence of human TI-VAMP (see figure 8). SEQ ID V3 refers to the DNA sequence of an isolated polynucleotide . the sequence of which corresponds to a sequence coding for M " to the end of SEQ ID V6. that is to say corresponds to a position 376-732 DNA fragment of SEQ ID V5. All of these pohnucleotides are particularly useful for transfection into a cell such as an animal cell, a human cell, a cell line a plant cell, an eucaryotic cell a protist Thev can be directly electroporated into a cell such as a neuronal or dendritic cell (see examples below) When appropriate, transfection vectors such as plasmids or retrovirus which comprise at least one polynucleotide according to the invention can alternatively oe constructed by the skilled person Preferably, said at least one polynucleotide is comprised in said transfection vector in a coding position Appropπate promotors namely comprise those of cytomegalo irus or of TI- VAMP himself (S naptobrevin like gene 1 Matarazzo et a' Gene 1999 240233-238) When the transfection vector comprises at least one Nter polynucleotide ofthe invention, it is herein referred to as "Nter" transfection vector When the transfection vector comprises at least one "deleted" polynucleotide of the invention, it is herein referred to as "deleted" transfection vector Examples of such vectors and of such transfection notably comprise viral vectors, retroviral vectors, adenoviral vectors, adeno-associated vectors (Aav). lentivirus herpes virus plasmids. or the like Several of them are illustrated in the below examples Advantageous transfection vectors namely comprise recombinant adeno-associated irus (see example 4 below , and see also Berns and Bohensky 1987 Advances in Virus Research (Academic Press. Ine ) 32 243-30 " . Kaphtt et al 1994. Nature Genetics 8 148-154 , US 5.175,414 , US 5.139.941. Vincent et al 1990 Vaccines 90 (Cold Spring Harbor Laboratory Press) . Kotin et al 1994 Human Gene Therapy 5 793-801 , Du et al 1996 Gene Ther 3(3) 254-261 . Slack and Miller 1996. Curr Opm Neurobiol 6(5) 576-583) Recombinant adeno-associated virus comprising a: least one Nter polynucleotide or at least one "deleted" polynucleotide ofthe invention will be herein referred to as the Nter adeno-associated virus ofthe invention, and to the "deleted' adeno-associated virtis o the invention respectively They are particularly useful for transfectmg cells such as neuronal celis They represent useful agents for gene therapy or anti-sense therapy The present inv ention encompasses their use for the production ot a pharmaceutical composition or a drug ot the inv ention ( see below ) and also encompasses the pharmaceutical compositions and drugs resulting therefrom The inv ention further encompasses any cell that has been genetically engineered cell so as to comprise at least one product selected from - the group consisting of the Nter poh nucleotides according to the inv ention, the Nter transfection v ectors according to the inv ention (and notably the Nter adeno-associated v irus of the inv ention ) this group being referred to as the "Nter' cells of the invention or - the group consisting of the "deleted" pohnucleotides according to the invention, the transfection v ectors according to the inv ention (and notably the "deleted" adeno-associated v irus of the invention), this group being referred to as the "deleted" cells of the inv ention Preferred Nter and "deleted' cells of the inv ention produce Nter. or respectiv ely , "deleted" poly peptides according to the inv ention Preferred cells are protist cells eucary otic cells human cells, animal cells such as animal ovary cells, human or animal neuronal cells, dendritic cells, tumor cells The invention notably encompasses any dendritic or neuronal cell which has been transfected with an adeno-associated v irus of the invention According to a further complementary aspect of the invention, there are prov ided new products enabling the isolation of the po nucleotides of the invention The inv ention indeed encompasses any pair of oligonucleotides characterized in that it is capable under standard PCR conditions to ampli fy at least one Nter poly nucleotide according to the inv ention Such ohgonucleotide pairs namely comprise the SEQ ID V I 1. SEQ ID V 12 pair (see example 1 below ) The inv ention correspondingly also encompasses any pair of oligonucleotides characterized in that it is capable under standard PCR conditions to ampli at least one "deleted" poly nucleotide according to the inv ention Such oligonucieotide pairs namely comprise the SEQ ID V 1 5 SEQ ID V 16 pan ( see example 1 below ) By standard PCR conditions, it is herein meant PCR conditions that enable the skilled person to amplify from a polv nucleotidic population the desired pol nucleotide at the desired purity or specificity The adjustment of such conditions are of common know ledge Examples of appropriate conditions include the calculation of the melting temperature of the primers according to common know ledge in the art. and a choice of MgCF concentration so as to establish the desired stringency These ohgonucleotidic pairs of the inv ention allow the isolation of Nter poh nucleotides according to the invention, and respectively "deleted" poh nucleotides according to the invention This isolation can be performed from a poly nucleotide population extracted from cells such as human cells A standard w ay to proceed is to place at least one ohgonucleotidic pair according to the inv ention into contact w ith such a poly nucleotide population under conditions appropriate to PCR amplification as abov e-defined This method of the invention namely allow s the skilled person to obtain any desired variant and/or fragment of Nter polvnucleotides and "deleted" polvnucleotides of the invention It further enables to isolate mutant non-functional forms of human or animal Nter and "deleted" pohnucleotides of the invention The present invention thus encompasses any isolated polynucleotide which is such as obtained by using on a poly nucleotide population at least one pair of oligonucleotides according to the inv ention Appropriate poly nucleotide populations namely comprise those extracted from human or animal cells. from human or animal normal cells, from human or animal pathological cells from human or animal nerv e or neuronal cells from human or animal tumor cells An easy w ay to proceed is v ia PCR Once such poh nucleotides are isolated, it is of common know ledge to the skilled person to deduce from them the amino acid sequences that correspond to them According to aspect of particular interest for industrial application, the inv ention prov ides w ith pharmaceutical compositions w hich comprise at least one product selected from the group consisting ot the Nter poly peptides according to the inv ention, the Nter poh nucleotides according to the inv ention, the Nter transfection v ectors according to the inv ention ( and notably the Nter adeno-associated v irus of the inv ention), and the Nter cells according to the inv ention Such a pharmaceutical composition may notably be a drug, w hich can be administered to a human or to an animal In this case, the drug of the inv ention may comprise said at least one product in a quantity appropπate for inhibiting a cell membrane traffic, and or a function involving a TeNT-msensitive pathw ay , and/ or a function inv olving a TeNT-resistant VAMP such as TI-VAMP. and or a cell fusion or cell exocytic function, and/ or the formation of complexes inv olv ing a TeNT-insensitiv e VAMP such as TI-VAMP. and or a cell undesired motility such as the motihty of cells susceptible of forming metastasis Pharmaceutical compositions of the invention thus notably comprise anti-tumor drugs It also relates to the use of such products for the production of such a pharmaceutical composition According to another aspect of particular interest for industrial application, the invention provides with pharmaceutical composition comprising at least one product selected from the group consisting of the "deleted" polypeptides according to the inv ention, the "deleted" poh nucleotides according to the inv ention, the "deleted" transfection vectors according to the inv ention (and notably the "deleted" adeno-associated v irus of the inv ention), and the "deleted" ceils according to the in ention Such a pharmaceutical composition may notably be a drug, which can be administered to a human or an animal In this case, the drug of the inv ention may comprise said at least one product in a quantity appropriate for stimulating a cell membrane traffic, and/or a function involv ing a TeNT-resistant pathway and or a function inv olving a TeNT- msensitiv e V AMP such as TI-\ AMP and or a cell fusion or a cell exocytic function, and or the formation of complexes inv olv ing a TeNT-insensitiv e V AMP such as TI-VAMP. and or a neuπte outgrow th ( axonal and or dendritic outgrow th ), and or a neuronal maturation, and or a neuronal differentiation and or appropπate for stimulating memory and or learning Pharmaceutical compositions of the invention thus notably comprise drugs intended for the therapy and or palliation and'or prev ention of spinal cord trauma It also relates to the use of such products for the production of such a pharmaceutical composition The pharmaceutical compositions and drugs of the invention may further comprise any additiv e, co-agent, buffer appropriate to the application for which it is intended The formulation of such compositions and drugs can be chosen and adjusted by the skilled person in function of the precise reactiv e agent chosen (polypeptide poly nucleotide transfection v ector cell), in function of the additiv es co-agents and'or buffer that hav e been chosen, and has to take into account the administration route that is desired ( topical, oral, injection subcutaneous, implant, patch, spray , transfection etc ) The invention also provides with new means making use of the new products of the invention, and sharing w ith them the same or corresponding feature of the inhibition function of which is capable the N-terminal domain of a TeNT- msensitive VAMP such as TI-VAMP The invention notably provides w ith a method for identifying a pharmaceutical agent capable of stimulating a cell function selected from the group consisting of the cell functions involv ing a membrane traffic, the cell functions inv olving a TeNT-resistant pathw ay the cell functions inv olv ing the formation of complexes w ith a TeNT-insensitiv e VAMP such as TI-VAMP. the cell functions inv olv ing at least one TeNT-insensiti e \ W1P such as TI-V AMP the cell functions inv olv ing a fusion, or an exocy tic ev ent, the cell functions inv olv ed m neuπte outgrowth, in neuronal maturation in neuronal di fferentiation in neuronal or dendritic v iability in memorv ability in learning capacity characterized in that it corPDnse-, at least one step selected trom the group consisting of - the identification of an agent that is capable under phy siological conditions of blocking or diminishing the inhibition effect that is observ ed w hen the cy toplasm of said cell is placed into contact w ith at least one product selected from the group consisting of the Nter poly peptides according to the inv ention, the Nter poh nucleotides according to the invention, the Nter transtection v ectors according to the invention, the Nter adeno-associated v irus of the inv ention, the Nter cells according to the invention, under conditions appropπate to cell membrane trafficking - the identification of an agent that is capable under phy siological conditions to compete w ith a 'binding' product according to the inv ention for binding to at least one Nter polypeptide of the inv ention. - the identification of an agent that is capable under phy siological conditions of stimulating the formation of complexes involving at least one "deleted" polypeptide according to the inv ention, and at least one t-SNARE (such as SNAP25. SNAP23. syntaxm l . sy ntaxm3 for TI-VAMP). the identification of an agent that is capable under phy siological conditions of exerting an additional or synergic effect on the cell function that is observed when the cy toplasm of said cell is placed into contact w ith at least one product selected from the group consisting of the "deleted" poly peptides according to the inv ention, the "binding" products according to the inv ention, the "deleted" polv nucleotides according to the ind ention the "deleted" transfection v ectors according to the in ention, the "deleted" adeno- associated v irus of the invention, the "deleted cells according to the inv ention under conditions appropπate to cell membrane trafficking. - the identification of an agent that is capable under phy siological conditions of prev enting the formation ot complexes betw een compounds w hich comprise at least one Nter poly peptide of the invention, or of disrupting or destabilizing such complexes The invention also prov ides w ith a method for identih mg a pharmaceutical agent capable of inhibiting a cell function selected from the group consisting of the cell functions involv ing a membrane traffic, the cell functions involving a TeNT-resistant pathway the cell functions inv olv ing the formation of complexes w ith a TeNT-insensitive VAMP such as TI-VAMP, the cell functions inv olving at least one TeNT-insensitiv e VAMP such as TI-VAMP. the cell functions inv olv ing a fusion, or an exocy tic ev ent the cell functions inv olv ed in cell motilitv . the cell functions inv olv ed in the formation of metastasis, characterized in that it comprises at least one step selected from the group consisting of - the identification of an agent that is capable under physiological conditions of stimulating the inhibition effect that is observ ed when the cytoplasm of said cell is placed into contact with at least one product selected from the group consisting of the Nter polypeptides according to the invention, the Nter polvnucleotides according to the invention, the Nter transfection v ectors according to the invention. the Nter adeno-associated virus of the inv ention, the Nter cells according to the inv ention, under conditions appropπate to cell membrane trafficking. the identification of an agent that is capable under physiological conditions ot inhibiting the formation of complexes inv olv ing at least one "deleted" poly peptide according to the inv ention, and at least one t-SNARE (such as SNAP25 SNAP23 sy ntaxm l . sy ntaxιn3 for TI-VAMP). - the identification of an agent that is capable under phy siological conditions ot exerting an inhibitory effect on the cell function that is observ ed when the cy toplasm of said cell is placed into contact w ith at least one product selected from the group consisting of the "deleted" poly peptides according the inv ention the "binding" products according to the inv ention the ' deleted" poh nucleotides according to the inv ention, the 'deletec, transfection v ectors according to the invention, the "deleted" adeno-associated v irus of the invention, the "deleted" cells according to the invention under conditions appropπate to cell membrane trafficking, the identification of an agent that is capable under phy siological conditions to lyse a "binding" product of the invention w hich is capable of inhibiting at least one of the biological properties a Nter poly peptide can show , as abov e-defined. - the identification of an agent that is capable under physiological conditions of stimulating the formation of complexes between compounds which comprise at least one Nter polypeptide of the invention, or of stabilizing such complexes, or of prev enting the disruption of such complexes For the identification methods of the inv ention any appropriate cell is convenient It notably includes human and animal, normal and pathological cells, neuronal cells, tumor cells Said identification may be performed by any means the skilled person find appropπate This namely includes the screening of chemical and/or biological libraπes for an agent hav ing the desired capacity Screening in function of the capacity ot the test agent to bind onto a t-S ARE ( sucn as SN AP25. SNAP23 sy ntaxin l and/or syntaxm3 for TIΛ AMP) may inv olv e the association of the test products w ith a tag such as GST. GFP the immobilization ot at least one appropriate t-SNARE on a solid support such as a membrane and the detection by antibodies of those test products w hich arc retained onto said solid support ( see e g ov erlay assay in the abov e example 1 ) Said identification may also be performed by ELIS A techniques The present inv ention also encompasses anv pharmaceutical agent such as obtained by a method of identification according to the inv ention These agents are regulatory agents the ones obtained by the first method are stimulation agents, the ones obtained by the latter method are inhibition agents A further aspect of industrial interest relates to the use of at least one product selected from the group consisting of the Nter poly peptides according to the invention, the Nter poh nucleotides according to the inv ention the Nter transfection v ectors according to the inv ention the Nter Adeno-associated v irus of the inv ention, the Nter cells according to the inv ention the inhibition pharmaceutical agents according to the inv ention, for the production of a drug intended for at least one effect selected from the group consisting of inhibiting a cell membrane traffic, inhibiting a vesicular transport, inhibiting a function involving at least one TeNT-resistant pathway , inhibiting a function involving a TeNT-insensitive VAMP such as TI-VAMP. inhibiting the formation of complexes involving at least one TeNT-insensitiv e VAMP such as TI-VAMP and at least one t-SNARE (such as SNAP25. SNAP23. syntaxin 1. syntaxin 3. for TI-VAMP). inhibiting a cell moti ty such as the motihty of cells susceptible of forming metastasis The inv ention notably encompasses an anti- tumor medicament comprising at least one of these products as an activ e principle The po nucleotides which are the anti-sense of the "deleted" poh nucleotides of the inv ention may also be used as acti e principle in such a drug. Such anti-sense polvnucleotides. and such a pharmaceutical composition or drug are therefore also encompassed by the present application. The present invention further relates to the use of at least one product selected from the group consisting of the "deleted" poly peptides according to the invention, the "binding" products according to the invention, the "deleted" polvnucleotides according to the inv ention, the "deleted" transfection vectors according to the invention, the "deleted" adeno-associated virus of the invention, the "deleted" cells according to the invention, the stimulation pharmaceutical agents according to the invention, for the production of a drug intended for at least one effect selected from the group consisting of stimulating a cell membrane traffic, stimulating a vesicular transport, stimulating a function involving at least one TeNT-resistant pathway, stimulating a function involving a TeNT-insensitive VAMP such as TI- VAMP, stimulating the formation of complexes involving at least one TeNT- insensitive VAMP such as TI-VAMP and at least one t-SNARE (such as, for the TI-VAMP : SNAP25. SNAP23. syntaxin 1. syntaxin 3). stimulating axonal and/or dendritic outgrowth, stimuling. neuronal maturation, stimulating neuronal differentiation, preventing or decreasing neuronal. axonal. or dendritic apoptosis, stimulating memory and/or learning capacity, curing and/or palliating and/or preventing spinal cord trauma, curing and/or palliating and/or preventing neuro-degenerative disorders, curing and/or palliating and/or preventing sclerosis. The invention encompasses such a medicament intended for stimulating memory and/or learning capacity, curing and/or palliating and/or preventing spinal cord trauma, curing and/or palliating and/or preventing neuro-degenerative disorders, curing and/or palliating and/or preventing sclerosis, which comprises at least one of these products. The polvnucleotides which are the anti-sense of the Nter polvnucleotides of the invention may also be used as active principle in such a drug. Such anti-sense poh nucleotides. and such a pharmaceutical composition or drug are therefore also encompassed by the present application Another aspect of the inv ention that is of industrial interest relates to a method tor diagnosing an undesired state and or tor assessing the efficiency of a medical treatment, and or for assessing the ev olution ot an undesired state, characterized in that it comprises at least one step selected from the group consisting of - detecting, in a biological sample that a product selected from the group consisting of the "deleted" poly peptides according to the inv ention, the "binding" products according to the inv ention, the "deleted" poh nucleotides according to the invention, the "deleted" transfection v ectors according to the inv ention, the "deleted" adeno-associated v irus of the inv ention, the "deleted" cells according to the invention is present in a quantity or concentration significantly different from the standard level of quantity or concentration (this step will be referred to as step a ). or - detecting in a biological sample that the expression lev el of a Nter poly peptide according to the inv ention is significantly different from the standard expression level (step b ). or - detecting in a biological sample that the quantity or concentration of complexes involving compounds which comprise at least one Nter polypeptide according to claim 1 , is significantly different from the standard level (step c ) Said biological sample may notably be a peripheral blood, tissue or biological liquid sample. It remarkably may correspond to a neuronal cell sample, or to a tumor cell sample Said undesired state may correspond to any state selected from the group consisting of the states inv olv ing the deregulation of a cell membrane traffic, of a cell TeNT-resistant pathway , of a cell function involving the activ ity of a TeNT-insensitive VAMP such as TI-VAMP. of the formation of complexes betw een a TeNT-msensitiv e \ AMP such as TI-VAMP and a t-SN ARE ( SNAP 25. SNAP 23. syntaxin 1. syntaxin3 are t-SNARE for TI-VAMP). of a fusion or an exocytic event. It remarkably may correspond to a state involving the disregulation of the differentiation and or of the maturation of neuronal cells ( disregulation of neuπte outgrowth ) : this is for example the case of spiral cord trauma, and also of neuro-degenerativ e disorders, and of certain sclerosis. Said undesired state may also correspond to a state involving the disregulation of the motilitv of he cells, as this is in particularly the case for tumor cells disseminating so as to form metastasis. Standard is herein meant as the average value observed in healthy patients. When the quantity 'concentration level detected according to the above-defined step a. is significantly superior to the standard level, and/or when the expression level detected in the above-defined step b. is significantly inferior to the standard expression level, and/or when the quantity (or concentration) of complexes as defined in the above step c. is higher than the standard quantity (or concentration), the state concerned is disregulated in the sense of an excess of stimulation ( superior level in step a. and/or step c. ) or of a lack of inhibition (inferior level in step b. ). This may be the case e g. of proliferating and disseminating tumor cells. When the quantity/concentration level detected according to the above-defined step a. is significantly inferior to the standard level, and/or when the expression level detected in the above-defined step b. is significantly superior to the standard expression level, and/or when the quantity (or concentration) of complexes as defined the above step c. is lower than the standard quantity (or concentration), the state concerned is disregulated in the sense of a lack of stimulation (inferior level in step a. and/or step c.) or of an excess of inhibition (superior level in step b.). This may be the case e.g of non- or insufficiently maturing and/or differentiating neuronal cells. The invention also encompasses the kits for implementing this method of the invention. Such kits may comprise at least one of said product of the inv ention possibh together w ith appropπate v isualization agent such as GFP or GST tag The present inv ention further relates to a method tor identify ing a compound capable ot acting as a biological effector ot a TeNT-insensitiv e \ AMP such as TI-VAMP characterized in that it comprises at least one step selected from the group consisting ot - the detection of a compound w hich is capable under ph siological conditions of binding to a Nter poly peptide according to the invention the detection of a compound w hich is capable under phy siological conditions of diminishing the inhibition effect that is observed when the cy toplasm of a cell expressing said TeNT-msensitiv e VAMP is placed into contact with at least one product selected from the group consisting of the Nter poly peptides according to the invention, the Nter pohnucleotides according the inv ention, the Nter transfection v ectors according to the inv ention the Nter Adeno-associated v irus of the invention the Nter cells according to the invention under conditions appropπate to cell membrane trafficking - the detection of a compound which is capable under physiological conditions of exerting an additional or synergic effect on the cell function that is observed w hen the cy toplasm of a cell expressing a TeNT-insensiti e VAMP such as TI-VAMP is placed into contact w ith at least one product selected from the group consisting of the "deleted" polypeptides according to tne invention, the "binding" products according to the invention the "deleted" poh nucleotides according to the inv ention the ' deleted' transfection v ectors according to the inv ention, the "deleted ' adeno-associated v irus of the inv ention, the "deleted" cells according to the invention, under conditions appropπate to cell membrane trafficking Any cell may be appropπate It remarkably includes human or animal neuronal and tumor cells Said detection step may be performed according to the common know ledge of the persons skilled in the identi fication of a compound hav ing the desired capacity It namely includes screening of chemical and'or biological libraries An effector compound such as identi fied by the method o the inv ention is of particular use for modulating the activ ity of its TeNT-insensitiv e VAMP receptor It may e g be used as a co-agent in the applications described herein Other and further characteristics, adv antages, and v ariant embodiments of the inv ention can be found by the skilled persons from the below -given examples These examples are given for illustration purposes only , they do not limit the scope of the invention. In particular, while these examples illustrate the invention for the human normal TeNT-insensitiv e VAMP TI-VAMP. the skilled person can proceed similarly with other TeNT-resistant VAMP, and adjust, w hen appropriate, the operating conditions Figure 1 illustrates the localisation of membrane markers in horizontal confocal sections of staurosporme-differentiated PC 12 cells PC 12 cells were treated with l OOnM staurosporine for 24 hours, fixed and processed for lmmunofluorescence with anti-sy naptobrevin 2 (Sb2) and anti- TI-VAMP (TIVAMP), anti-SNAP25 (SNAP25) or anti-sy naptotagmin I (Sy t I) antibodies. The cells w ere then observed by confocal microscopy Note the lack of co-localisation of synaptobrevin 2 and TI-VAMP. the restricted localisation of SNAP25 at the plasma membrane and the concentration of synaptotagmin I at the tip of neurites Bar" 5μm Figures 2 illustrate the dynamics of GFP-TI VAMP- vesicles : PC 12 cells transfected with GFP-TI VAMP w ere treated w ith staurosporine for 5 hours and observed under time-lapsed ideomicroscop in the presence of staurosporine Figure 2\ illustrates that the GFP-TIVAMP vesicles accompany the growth of neuπtes Transmission and fluorescent light images were recorded everv 2 min over a period of 8 hours Images recorded evεiv 24 min through the middle peπod ot the whole recording are shown The inset shows a higher magnification ot a growing neuπte Arrows indicate regions of this neuπte where GFP-TIVAMP concentrates Bar 5um Figure 2B illustrates the GFP-TIA AMP vesicle dvnamics in neuπtes Fluorescent light images were recorded everv 15s over a peπod of 30 min (bottom right number time in s) Images recorded during a limn peπod ofthe recording are shown The arrow indicates a GFP-TIVAMP vesicles which is moving anterogradly Bar lum Figure 3 illustrates TI-VAMP recvcles at the neuritic plasma membrane PC 12 cells transfected with TI\ AMP-GFP or GFP-TIVAMP and treated with staurosporine for 20 hours were placed on ice incubated with monoclonal antibody anti-GFP (5ugml) tor 15 min and directly fixed (15 ' 4°C) or further incubated at 37°C for 15 m (-15 " /37°C) or 60 mm (+60737°C) before fixation Note the dense labelling of the neuritic plasma membrane in the 1574°C and -15 " '37°C conditions Full loading ofthe GFP- TIVAMP compartment is reached in the -60 ' 37°C condition Bar 5um Figures 4 illustrate the biochemical properties of the TI- VAMP / SNAP25 complex Figure 4A illustrates that TI-VAMP forms a complex with SNAP25 in Triton XI 00 extract of rat brain Immunoprecipitation with antι-SNAP25 antibodies was performed from Triton XI 00 soluble extract of rat brain as described in the Materials and Methods section of example 1 and immunoprecφitated proteins were detected by western blot anahsis with the indicated antibodies ( s naptobrevin 2 Sb2 cellubrev m Cb. L unbound. B bound to anti- SN AP25 immunobeads) The bound fraction corresponded to a 65-fold enrichment compared to unbound The SN AP25 TI-\ AMP complex seemed mot e abundant than the SN AP25 s naptobrev in 2 one but this m only reflect a low er expression lev el of TI-VAMP compared to sv naptobrev in 2 in the adult bi ain Note that cellubrev m did not co-immunoprecipitate w ith SN AP25 Figure 4B illustrates the structure of TI-\ AMP and TIV AMP-deπved constructs TI-VAMP is composed of three domains the Nter domain ( amino- acids 1 to 120) the coiled-coiled domain, also called R-SN ARE motif (CC ammo acids 121 to 180), and one comprising the transmembrane domain and a short luminal domain (TM amino acids 181 to 220 ) These domains were tagged w ith GFP and GST as depicted Figure 4C illustrates that the Nter domain of TI-V AMP inhibits binding of TI- VAMP to SNAP25 The binding of GST. GST-Cy t-TI V AMP GST-Nter-TIVAMP or GST-CC- TIVAMP w as measured by ov erlay ov er immobilized 6xhιs-SNAP25 ( indicated by the arrow ) GST-CC-TIVAMP bound efficiently to immobilized 6xhιs-SNAP25 Little binding of GST-Cyt-TI\ AMP and none of GST and GST-Nter-TIVAMP were observed As positiv e control, a strip was revealed with antι-6xhιstιdιne antibodies Figure 4D illustrates that the TI-VAMP mutant lacking the Nter domain co- immunoprecipitates with SNAP25 more efficiently than full-length TI-VAMP HeLa cells co-transfected w ith SNAP25 plus GFP-ΔNter-TIVAMP. GFP- TIVAMP. GFP-Nter-TIVAMP or GFP w ere ly sed and subjected to lmmuno- precipitation w ith mouse monoclonal antι-SNAP25 antibodies as described in the Materials and Methods section of example 1 The immuno-precipitated proteins were then detected by w estern blot w ith anti-GFP or antι-SNAP25 rabbit poly clonal antibodies The bound fraction corresponded to a 100-fold enrichment compared to the starting material ( SM) in the case of the GFP blot and to a 10-fold enrichment in the case of the SN.AP25 blot. Note that neither GFP-Nter-TIVAMP nor GFP co-immunoprecφitated ith SNAP25 Figures 5 illustrate the expression of the Nter domain of TI-VAMP inhibits neurite outgrowth. Figure 5A illustrates the effect of GFP. GFP plus TeNT. GFP plus BoNT E or GFP-Nter-TIVAMP on neurite outgrowth. PC 12 cells transfected w ith the indicated constructions and treated with staurosporine were fixed and direct fluorescence images were recorded. Representati e fields of the distinct phenotypes found are show n. Note the long neuritεs displayed both by the GFP and the GFP-TeNT-transfected cells compared with the shorter ones displayed by the GFP-rBoNTE and the GFP-Nter-TIVAMP-transfected cells (arrowheads). Bar: 25μm Figure 5B illustrates that GFP-Nter -TIVAMP and BoNT E inhibit neurite length. Percentage of neurites longer than 20um A minimun of 50 transfected cells of each type were recorded in blind, and the length of all their neurites was measured. The mean values (-■'- SE) of percentage of neurites longer than 20μm from three independent experiments are show n "p<0.03 (Student ' s t- test). Note the lack of effect of TeNT and that BoNT E and GFP-Nter- TIVAMP had a similar inhibitory effect on neurite length. Figure 5C illustrates the number of neurites per cell. The same randomly chosen transfected cells were use to quantify the number of neurites per cell Shown is the number of cells, expressed as the percentage of transfected cells, displaying 1 , 2, 3 or >4 neurites. The mean v alues (- - SE) of three independent experiments are shown. Note the lack of effect of TeNT and that both BoNT E and GFP-Nter-TIVAMP enhanced the of cells without neurites. Figure 6 illustrates the moφhology of GFP-Nter-TIVAMP expressing cells PC 12 cells transfected w ith GFP-Nter-TIVAMP and treated w ith staurosporine as in figure 5 w ere fixed, processed for double fluorescence by combining direct GFP fluorescence detection w ith indirect lmunofluorescence detection using the indicated antibodies Representativ e GFP-Nter-TIVAMP transfected cells w ithout or w ith short neuπte(s) are shown in horizontal confocal sections Sy ntaxin (Stx) 1 and b and s naptobrev in 2 ( Sb2 ) hav e a localisation similar in untransfected as in GFP-Nter-TIVAMP expressing cells. Sy naptotagmm I immunoreactiv ity w as w eaker in GFP-Nter-TIVAMP transfected cells than in untransfected cells Bar l Oum Figures 7 illustrate that the expression of a "deleted" polypeptide of the invention (TI-VAMP lacking the Nterminal domain) enhances neurite outgrowth Figure 7A illustrates the moφhology of PC 12 cells transfected with GFP- TIVAMP or GFP-ΔNter-TI-VAMP The cells w ere transfected. treated with staurosporine as in figure 5. fixed'permeabilized and processed for double fluorescence by combining direct GFP fluorescence detection w ith indirect imunofluorescence detection using Texas Red-phalloidin to visualise the actin filaments. Note the occurrence of numerous filopodia in the neuritic tip of the GFP-ΔNter-TI-VAMP transfected cell. Bar- l Oμm Figure 7B illustrates the GFP-ΔNter-TIVAMP increases neuπte length. A minimun of 100 transfected cells of each type w ere recorded in blind, and the length of all their neurites w as measured The mean values (- ■ - SE) of the percentage of neuπtes longer than 30μm or 50μm from three independent experiments is show n * * * indicates p< 0.001 (Student ' s t-test). Figure 7C illustrates the GFP-ΔNter-TIVAMP enhances formation of SNARE complexes. A Triton X- 100 soluble extract was prepared from PC 12 cells transfected w ith GFP-TIVAMP. GFP-ΔNter-TIVAMP or GFP-Sb2 and subjected to ov ernight immunoprecipitation w ith monoclonal anti-GFP antibodies Immunoprecipitated proteins w ere resolv ed in SDS-PAGE follow ed bv western blot anah sis w ith the indicated antibodies Note the increased co-immunoprecipitation of endogenous SN AP25 w ith GFP-ΔNter- TI\ AMP compared w ith GFP-TIø AMP The histogram in the right side show s the quantification of the amount of endogenous SN AP25 immunoprecipitated normalise to the amount of GFP-tusion protein immunoprecipitated from two independent experiments * *p<0 01 (Student s t-test) Figure 8 illustrates the complete human TI-V AMP amino acid ( SEQ ID V6) and pol peptide (SEQ ID V5) sequences Figure 9 illustrates that the expression of the amino-termmal domain of TIVAMP specificalh affects the distribution of dendritic markers in hippocampal neurons 4 dav s old hippocampal neurons from embry onic E l 8 rats were transfected w ith GFP or GFP-Nter-TI\ AMP and after24 hours fixed and stained for the indicated proteins Note the expected dendritic localization of EAAC l m control neurons and in neurons transfected with GFP (right upper panel and nontransfected cell in the right middle panel) compared to its general low er expression and specifically its absence from the dendπtes in cells expressing Nter-TIVAMP (transfected cell in the right middle panel) By contrast, the level of expression and the localization of GluRl were not affected by expression of GFP-Nter-TIVAMP (compare the two cells in the right lower panel) Bar. 2 1 um Figures 10A, 10B, IOC, 10D, 10E illustrate that the expression of the amino-terminal domain of TIVAMP inhibits axonal and dendritic growth Figure 10A: Hippocampal neurons from embryonic E l 8 rats were transfected after 1 div (div = days in vitro) with GFP or GFP-Nter-TIVAMP and the axonal length measured 24h later: shown are the mean values ι - - SEM) of betw een 40 and 60 analysed cells Figure 10B: Cells transfected as in panel A after 1 div or 4 div were recorded 24 hours later and the dendritic length was measured. Figure IOC: Cells transfected as in figure 10.A after 1 div or 4 div were recorded 24 hours post-transfection and the number of dendrites on each cell was counted. Figure 10D: Cells transfected as in figure 10.A after 4 div were stained 24 hours later for EAAC l ; shown is the mean values (-* - SEM) of percentage of GFP or Nter-TIVAMP positive dendrites labeled also for EAAC l . Figure 10E: Hippocampal neurons from embryonic E l 8 rats were micro- injected 4 hours after plating with control rabbit IgGs or with affinity-purified anti-TIVAMP rabbit polyclonal antibody. TG I L I 6. After 20 hours cells were fixed, and the number of dendrites on each injected cell was measured : shown are the mean values (-■ - SEM) of a minimum of 140 recorded cells. * *. p<0.006: * . p<0.06. Figures 11A, 11B, 11C, 11D illustrate that the expression of the amino-terminal domain of TIVAMP induces apoptosis. Figure 11 A: Cortical-striatal neurons from intact embrvonic brains were electroporated with the indicated constructs and cultured for 24h in the absence (left panels) or presence (right panels) of the caspase inhibitor zVAD. Observe the increase in the number of transfected cells in zVAD-treated Nter- TIVAMP-electroporated cells compared to non treated cells. In the case of GFP-electroporated cells there is no difference between zVAD-treated or non treated cells. Bar, 100 μm. Figure 11 B : Quantification of the apoptotic effect of the amino-terminal domain of TIVAMP in cells treated as in figure 11A: shown are the mean values ι - - SEM) ofthe number of positive cells or, each coverslip Figure 11 C : Quantification ofthe effect in axonal length ofthe expression of the amino-terminal domain of TIV.AMP in cells treated as in figure 11 A Shown are the mean values (- - SEM) of a minimum of 40 cells Figure 1 ID: Neurons infected with Aav carrying GFP or Aav carrying GFP- Nter-TIVAMP fixed 3 days after infection. A representative cell of each type is shown. Note that the cell expressing GFP displays neurites and a normal nucleus compared to a noninfected cell, while the cell expressing Nter- TIV.AMP is round, with no neurites and presents a typical apoptotic nucleus as seen with DAPI staining. Bar.20 μm. Figure 12 illustrates that the moφhology of neurons expressing TIVAMP or ΔNter-TIV.AMP. Intact brains from embryonic El 3 mice (upper panels) or cortica-striatal neurons from embryonic E16 rats (lower panels) were electroporated or infected with the indicated Aa 5. respectively. Cells in primary culture were fixed after 2div (electroporation) or 3div (Aavs). Note the punctuate distribution in the cell body and along the axon of both full- length GFP-TIVAMP and GFP-ΔNter-TIVAMP and the fact that GFP-ΔNter- TIVAMP expressing cells present longer axons than cells expressing GFP- TIVAMP. Bar.20 μm (upper panels): 60 μm (lower panels). Figures 13A.13B illustrate that the exσression of ΔNter-TIVAMP activates axonal growth. Figure 13A: Quantification of he effect in axonal growth ofthe expression of ΔNter-TIVAMP in electroporated neurons. Neurons expressing GFP. GFP- TIVAMP. or GFP-ΔNter-TIVAMP were fixed after the indicated times, and the length of their axons was measured. In the upper panels are shown the mean v alues (- - SEM ) of percentage of axons longer than 50μm or 100 μm from three independent experiments: the lo er panels show tw o representative experiments. Figure 13B: Quantification o the effect on axonal grow th of the expression of ΔNter-TIVAMP in Aav -infected neurons Neurons expressing the indicated constructs w ere fixed after 3 or 6 div and their axonal length w as measured, each panel show s a representative experiment V p<0 001 . * . p<0.005 Figures 14A, 14B, 14C, 14D, 14E illustrate that GFP-ΔNter-TIVAMP does not colocalize w ith sy naptobrevin 2 Rat embry onic neurons were infected with Aav carrying GFP-ΔNter-TIVAMP. After 6 div . the cells were fixed and permeabilized. incubated with a polyclonal antibody anti-GFP and with a monoclonal antibody anti-synaptobrevin 2. and observed by confocal microscopy . Low magnification images are show n in Figure 14A. In all the other panels high magnification images of a cell body (Figure 14B). an axon (Figure 14C). a varicosity (Figure 14D) and a growth cone (Figure 14E). respectively are shown. GFP-ΔNter-TIVAMP (small arrows) does not co- localize w ith endogenous sy naptobrevin 2 (big arrow s in Figures 14B. 14C. 14D and 14E) in any of the different neuronal domains. A significant amount of GFP-ΔNter-TIVAMP was detected at the leading edge of the growth cone, in a -region devoid of synaptobrevin 2. Bars: Figure 14A. 90 μm ; Figures 14B. 14C. 14E. 4.6 urn : Figure 14D. 3 urn. EXAMPLE 1 : Materials and Methods Antibodies and clones: Rabbit serums (TG 1 1 and TG 16) directed against TIVAMP were purified by affinity chromatography in a column loaded with a GST-fusion protein of the coiled-coil domain of TI-VAMP (see below ) Mouse monoclonal antibodies directed against s naptobrevin 2 (clone 691 available trom Max Planck Institute. Goettingen FRG) SNAP25 (clone 20. Transduction Labs San Diego CA) GFP (clone " 1 and 131 Boehringer Mannheim FRG) syntaxin 6 (clone 30 Transduction Labs. San Diego CA) syntaxin 1 (FlPC-1. available trom Vale Lmversitv New Haven CT) glutathione S-transferase (generous gift from J -L Theillaud Institut Curie Pans France). TeNT light chain (TeNT-LC) (generous gift from FI Niemann Hannover Medical School Hannover FRG) rabbit polyclonal antibodies against the ectoplasmic domain of synaptotagmin 1 (890 " available from Yale Lmversitv New Haven CT), SNAP25 (MC9 available from Yale University New Haven. CT). GFP (Boehringer Mannheim. FRG) and histidine (Santa Cruz Biotechnology Inc. Santa Cruz. CA) have been descπbed previously Affinit -purified Cy2 and Texas Red-coupled goat anti-mouse and anti-rabbit immunoglobulins were purchased from Jackson ImmunoResearch (West Grove. PA) Rhodamine-coupled phalloidin was from SIGMA (Saint-Louis. MO) Alkaline Phosphatase coupled-sheep anti-mouse were from Promega (Madison. WI) The cDNAs of human TI-VAMP and cellubrevm were previously descπbed The cDNA sources were rat s naptobrevin 2 (R Scheller. Stanford University. Stanford. CA). for rat SNAP25A (R Jahn, Max Planck Institute, Goettingen, FRG). for TeNT-LC and BoNT-LC (H Niemann Hannover Medical School. Hannover. FRG) and for ratiometπc pHLuoπn (G Miesenbock. Sloan Kettermg Memorial Hospital New York, NY) Cell culture PC 12 cells were cultured in RPMI supplemented with 10 0/ o horse serum (HS) and 5% foetal calf serum (FCS) under standard conditions for PC 12 cells Cells were plated either on collagen-coated plastic dishes or on poly(L)lysιne plus collagen-coated glass covershps HeLa cells were cultured in DMEM supplemented ith 10% FCS DNA constructions: For production of N-terminal-GFP-fusion proteins the distinct cDNAs were cloned into the pEGFP-C3 vector (Clontech. Palo Alto. CA). The same empty vector was also used as a control in some ofthe neurite outgrowth assays. Full-length TIVAMP (TIV.AMP : aa : SEQ ID V6 : DNA : SEQ ID V5) . N-terminal domain-TIVAMP (Nter-TIVAMP. from M 1 to N ι:u : aa : SEQ ID V2 : DNA : SEQ ID VI). cytosolic domain-TIVAMP (Cyt- TIVAMP. from M 1 to K 1SS : aa : SEQ ID V8 : DNA : SEQ ID V7). ΔN- termina! domain-TIVAMP (ΔNter-TIVAMP. from M κ': to the end : aa : SEQ ID N°4 ; DNA : SEQ ID V3). and full-length synaptobrevin 2 (Sb2). were obtained by PCR using standard procedures and the following sets of oligonucleotides: 5'-ATGGCGATTCTTTTTGCTGTTGTTGCC-3 " (SEQ ID N°9) and 5'CTATTTCTTCACACAGCTTGGCCATGT-3 ' (SEQ ID V10) for TIVAMP; 5 ' -ATGGCGATTCTTTTTGCTGTTGTTGCC-3 ' (SEQ ID NT1) and 5'-CTTATTCTCAGAGTGATGCTTCAGCTG-3 ' (SEQ ID VI 2) for Nter-TI-VAMP; 5 ' -ATGGCG.ATTCTTTTTGCTGTTGTTGCC-3 ' (SEQ ID I 3) and 5 ' -ATCCTACTTGAGGTTCTTCATACACATGGCTC (SEQ ID V14) for Cyt-TI-VAMP: 5 ' -ATGAATAGCGAGTTCTCAAGTGTCTTA-3 " (SEQ ID V15) and 5 ' -CTATTTCTTCACACAGCTTGGCCATGT-3 " (SEQ ID VI 6) for ΔNter-TI-VAMP; 5 ' - ATGTCGGCTACCGCTGCCACCGTCCCG-3 ' (SEQ ID V17) and 5 ' - TTAAGAGCTGAAGTAAACTATGATGAT for Sb.2 (SEQ ID N°18). TIVAMP, Nter-TI-VAMP. Cyt-TI-VAMP and Cyt-Syb2 were cloned in pEGFP- C3 using the KpnLXbal sites, while ΔNter-TI-VAMP was cloned in Hindlll/Xbal sites. On figure 8. is shown the complete human TI-VAMP sequences SEQ ID V5 (DNA) and SEQ ID N°6 (amino acids: from M 1 to K :20 ). Nter amino acid sequence corresponds to human TI-VAMP sequence from M to N l2() (SEQ ID V2). Nter DNA sequence bears SEQ ID VI . ΔNter-TI-VAMP amino acid sequence corresponds to human TI-VAMP sequence from M 120 to K 220 ( SEQ ID V4 ) ΔNter-TI-VAMP DNA sequence bears SEQ ID V3. Cy tosolic TI-VAMP amino acid sequence corresponds to human TI-VAMP sequence from M 1 to K 188 ( SEQ ID V8). Cy t-TI-VAMP DNA sequence bears SEQ ID V7. The 101 amino acid fragment w hich lacks from ΔNter-TI-VAMP by comparison w ith the complete human TI-Y.AMP sequence, i.e. the M '-A 1 fragment, bears SEQ ID V20. Its corresponding DNA sequence bears SEQ ID NT 9. For production of the C-terminal-GFP ( ratiometic pHLuorin in this case) fusion protein of TIVAMP. TIVAMP cDNA bearing a BamHI site in its 3 ' was obtained by PCR using the 5 ' - GGATCCTTTCTTCACACAGCTTGGCCA-3 ' (SEQ ID V21) and 5 ' - CTATTTCTTCACACAGCTTGGCCATGT-3 " (SEQ ID V22 ) oligonucleotides. and cloned in the pCR3.1 -L ' ni vector (Clontech. Palo Alto. CA). Ratiometric pHLuorin was then cloned in the BamHLEcoRI sites. Nter- TIVAMP. Cyt-TIVAMP. and coiled-coiled domain of TIVAMP (CC- TIVAMP: from E 1 19 to K 188 ) were fused to glutathione S-tranferase (GST) gene by cloning in pGEX4T vector (Pharmacia. Saclay, France). Overlay assay: The corresponding GST fusion proteins and GST alone were produced and purified as previously described. 6xhis-tagged SNAP25A (6xhisSNAP25. bacterial strain is available from G. Schiavo. ICRF. London. UK) was purified. 6xhisSNAP25 w as run on SDS-PAGE and w estern blotted onto Immobilon-P membrane (Millipore. Bedford, MA). The amount of 6xhisSNAP25 corresponds to 1.25μg/mm of membrane. 4mm strips of the membrane were cut and incubated in 150mM NaCl. 5° o non fat dry milk. 50mM phosphate pH " 5 buffer for 1 hour at room temperature The strips w ere then incubated w ith l OnM the GST-fusion proteins ov ernight at 4 C C in buffer B ( 3° o BSA 0 1 % Tw een 20. 20mM Tπs pH " 5 ) containing 1 mM DTT The strips w ere rinsed three times in buffer B at room temperature incubated w ith anti-GST antibodies in buffer B for 1 hour, rinsed in buffer B three times and incubated w ith alkaline phosphatase-coupled sheep anti-mouse antibodies The detection w as carried out simultaneously for all the strips for the same time using a kit from Promega (Madison. WI) Cell transfection PC 12 or HeLa cells w ere try psmized. washed and resuspended at a density of 7 5- 10 x 10 6 cells/ml in Optimix (Equibio. Boughton Monchelsea. UK) Electroporation was performed with l Oμg DNA in a final v olume of 0 8ml cell suspension using a Gene Pulser II dev ice (Bio-Rad. Hercules. CA) w ith one shock at 950uF and 250 V When GFP was co- transfected with TeNT or BoNTE for monitoring the transfected cells, the plasmid carry ing the GFP gene w as added at double concentration in order to ensure that all the cells that uptake it do also uptake the plasmid carry ing the toxin Immediately after electroporation cells w ere washed w ith 5ml of complete medium before plating them for immunoprecipitation or lmmunofluorescence microscopy analysis Fiv e hours later, the outgrowth medium was removed and replaced with fresh medium containing l OOnM staurosporine (SIGMA. St Louis. MO) PC 12 and HeLa cells were processed 24 or 48 hours after transfection respectively For enhanced expression of the exogenous proteins. 5mM sodium butyrate w as added in all the cases during the last 6 hours before processing the cells Antibody uptake assay : PC 12 cells processed as indicated above were incubated in the presence of 5μg/ml anti-GFP antibody in culture medium for 15mιn on ice. 1 5mιn on ice then 1 5mιn at 3 "" C or 15mιn on ice then 60mιn at 37 C C. 24 hours after transfection with GFP-TIVAMP or TIVAMP-GFP. The cells were then washed twice with culture medium and twice with PBS. fixed with PFA and processed for immuno fluorescence. Immunocytochemistry : Cells were fixed w ith 4% PF.A and processed for immunofluorescence. Optical conventional microscopy was performed on a Leica microscope equipped with a MicroMax CCD camera (Princeton Instruments. Princeton. NJ). Confocal laser scanning microscopy was performed using a TCS confocal microscope ( Leica. Heidelberg. FRG). Images were assembled without modification using Adobe Photoshop (Adobe Systems. San Jose, CA ). Neurite outgrowth assay: Cells were fixed 24 hours after transfection. Between 20 and 100 randomly chosen fields for each condition were taken with a MicroMax CCD camera (Princeton Instruments. Princeton, NJ). resulting in the analysis of at least 50 transfected cells. A neurite was defined as a thin process longer than 5μm. Using the Metamoφh software (Princeton Instruments. Princeton. NJ) two parameters were scored in each case: the number of neurites per cell (from 0 to 4 or more neurites). and the length of each neurite, from the cell body limit until the tip of the process. The obtained data were analysed for their statistical significance with SigmaStat (SPSS Inc.. Chicago, IL). All the recordings and the Metamoφh analysis were done in blind. Videomicroscopy: Living PC 12 cells transfected and treated with staurosporine as described above were placed in complete medium in an appropriate chamber equilibrated at 37°C and 5% C0 2 . Cells were monitored with a MicroMax CCD camera (Princeton Instruments. Princeton. NJ) for as much as 9 hours, taking images both through phase contrast and FITC fluorescence everv 2 m or every 15 seconds Images were assembled using Metamorph (Princeton Instruments Princeton NJ) Immunoprecipitation Immunoprecipitation from rat brain was performed using a Triton \-100 soluble membrane traction prepared as follows two adult rat brains were homogenized with a glass teflon homogenizer (9 strokes at 900 rpm] in 25 ml of 032M sucrose containing a protease inhibitor cocktail All the steps were carried out at 4 C C After 10 min centπtugation at 800g the supernatant was centrifuged at 184000g for 1 hour obtaining a cvtosohc and a membrane traction in the supernatant and the pellet respectively The pellet was re-suspended in TSE (50mM Tπs pH 80 05mM EDTA.150mM NaCl) containing 1% Triton X-100 for 30 min and finally the insoluble material was removed by centπfugation at 184000g for 1 hour Immunoprecipitation with antι-SNAP25 antibodies and mouse control IgGs was performed from 2mg of proteins from the soluble extract Immunoprecipitations from transfected PC 12 or Hela cells were performed using a total Triton X-100 soluble fraction prepared as follows after two washes with cold TSE cells were lysed for 1 hour under continuous shaking with TSE containing l%Tπton X-100 and protease inhibitors The supernatant resulting from centπfugation at 20000g for 30 min was used for immunoprecitation After overnight incubation ofthe bram and cell extracts with the antibodies 50 ul of magnetic beads (Dynabeads, Dynal AS. Oslo, Norway) were added for 2-4 hours The magnetic beads were washed four times with TSE containing l%Tπton X- 100, eluted with gel sample buffer and the eluates were boiled for 5 mm and run on SDS-PAGE gels ΔNter-TI-VAMP amino acid sequence corresponds to human TI-VAMP sequence trom M 120 to K 220 (SEQ ID V3) ΔNter-TI-VAMP DNA sequence bears SEQ ID N°4 Cy tosolic TI-VAMP amino acid sequence corresponds to human TI-VAMP sequence from M to K , δa ( SEQ ID V7). Nter DNA sequence bears SEQ ID V8. The 101 amino acid fragment which lacks from ΔNter-TI-VAMP by comparison w ith the complete human TI-VAMP sequence, i.e the M ' -A 10 1 fragment, bears SEQ ID NT 9. Its corresponding DNA sequence bears SEQ ID V20 Results TI-VAMP dynamics in staurosporine-treated PC12 cells Differentiation of neurons and nerv e growth factor (NGF)-induced neurite outgrowth of PC 12 cells take several day s. On the contrary , staurosporine. a protein kinase inhibitor, induces maximal neurite outgrowth in 24 hours of treatment in PC 12 cells. Our neurite outgrowth assay is based on treating PC 12 cells with 100 nM staurosporine for 24 hours. These experimental conditions do not induce apoptosis in PC 12 cells. Figure 1 shows that synaptobrevin 2. TI-VAMP. SNAP25 and synaptotagmin I had a normal subcellular localisation in staurosporine-treated PC 12 cells. Synaptobrevin 2 concentrated in the perinuclear region and in neuritic tips. TI-VAMP positive vesicles were scattered throughout the cytoplasm and concentrated at the leading edge of extending neurites. Synaptotagmin I appeared almost exclusively in neurites and varicosities and SNAP25 was present throughout the plasma membrane. This pattern of immuno-staining was similar to that observed in NGF-treated PC 12 cells, demonstrating the validity of this cellular model to study neurite outgrowth. We produced TI-VAMP carrying a Green Fluorescent Protein (GFP) tag fused to the N-terminal end (GFP-TIVAMP. Figure 4B). Upon transfection of this construct in PC 12 cells. GFP staining w as indistinguishable from that of endogenous TI-VAMP ( compare figure 2 A w ith figure 1 ). thus discarding the possibility that fusion of the GFP tag could alter TI-VAMP trafficking W e then observ ed TI-VAMP dy namics by time lapsed v ideo-microscopy in staurosporine-treated PC 12 cells w hich had been prev iously transfected w ith GFP-TIVAMP ( figure 2) Fast grow ing neurites w ere recorded ev ery 2 min ov er periods of 3 to 9 hours. 5 hours after the onset of staurosporine treatment Figure 2 A display s transmission and fluorescent light images recorded every 24 min during 2 hrs 02 mm ( see also accompany ing mov ie) High magnification v iew of a neurite grow ing tow ards the bottom right of the image is show n in the inset At each time point GFP-TIVAMP containing v esicles distributed along this growing process, up to the leading edge of the growth cone (Figure 2A) Most movements of GFP-TIV AMP containing membranes were anterograde (Figure 2B) We then constructed another form of fluorescent TI-VAMP by introducing a GFP tag at the C-terminus (TIVAMP-GFP. Figure 4B) In this case, the GFP tag is exposed to the extracellular medium following exocy tosis of TI-VAMP containing v esicles TIVAMP-GFP transfected PC 12 cells w ere labelled w ith monoclonal antibodies directed against GFP while they were placed on ice. before fixation The labelling w as often concentrated at the tip of the growing neuπte (Figure 3) When the cells were allowed to internalise the antibody at 37°C, we observed a fast, time-dependent uptake After 15 mm at 37°C. the anti-GFP immuno-reactivity was seen in peripheral structures, very close to the plasma membrane w ith a low degree of overlap w ith the green signal emitted by the bulk of TIVAMP-GFP After 60 mm, most of the immuno-reactvity co-localised with TIVAMP-GFP, indicating that the anti- GFP antibody had reached the entire TIVAMP-GFP compartment We did not detect any plasma membrane labelling nor GFP antibody internalisation in GFP-TIVAMP transfected or untransfected cells (Figure 3) thus demonstrating the lack of capture of the antibody by fluid phase uptake Altogether, these studies demonstrate that the dv namics of TIN AMP containing v esicles v erv closely accompanies the growth of neurites and that the protein recy cles at the neuritic plasma membrane. The N-terminal domain of TI-VAMP inhibits SNARE complex formation Because TI-VAMP resists to NT treatment, new experimental approaches had to be dev eloped to study its function in living cells Toward this goal, we searched for mutated forms of TI-VAMP that w ould have impaired SNARL complex formation activity . We first identified SN.AP25 as a main physiological target SNARE ( t-SNARE ) of TI-VAMP. SN.AP25. a neuronal plasma membrane Q-SNARE. formed abundant SNARE complexes with TI-VAMP as seen by co-immunoprecipitation experiments performed from brain extracts. Cellubrevm. a v-SNARE that is expressed in glial cells but not in neurons, did not associate with SNAP25 thus showing that the SNARE complexes were not formed during solubilisation of brain membranes (figure 4 A). Protein sequence analysis of TI-VAMP shows that the protein has an original N-terminal (Nter) domain of 120 amino acids, located upstream of the coiled-coiled domain (also called R-SNARE motif) This Nter domain includes three regions predicted to be α heiical by Hydrophobic Cluster Analysis and Jpred. This is reminiscent of the Nter domain of syntaxin 1 , which comprises 3 α helices and inhibits lipid bilayer fusion. The Nter domain of Sso lp. the yeast homologue of syntaxin 1. inhibits the rate of SNARE complex formation. Similar Nter domains are present in the other plasma membrane but not in intracellular syntaxins. indicating that this function may be specific for exocytosis. This led us to prepare the following GST-fusion proteins: full cytoplasmic domain of TI-VAMP (GST-Cyt-TIVAMP). coiled- coiled domain alone (GST-CC-TIV.AMP) and Nter domain alone ( GST-Nter- TIVAMP) (Figure 4B). and to measure the binding of the corresponding proteins to immobilized 6xhis-SNAP25 in an overlay assay GST-CC- TIVAMP bound v ery efficiently immobilized hιs-SNAP25 w hereas GST-Cyt- TIVAMP bound v ery poorly . As controls. GST alone and GST-Nter-TIVAMP did not bind immobilized his-SNAP25 (Figure 4C ) HeLa cells do not express endogenous SN.AP25 so. we used them to study the association of SNAP25 w ith GFP-TIVAMP. GFP-ΔNter-TIVAMP. GFP-Nter-TIV.AMP ( Figure 4B ) or GFP. in vivo, following co-transfection. We measured the amount of GFP- tagged proteins co-immunoprecipitating w ith SNAP25 from Triton X- 100 soluble extracts GFP-ΔNter-TIVAMP formed more abundant SNAP25- containing SNARE complexes than GFP-TIVAMP. As controls. GFP and GFP-Nter-TIVAMP did not bind SNAP25 ( figure 4D). Altogether, w e propose that the Nter domain exerts an intramolecular inhibition of the SNARE complex formation activity of TI-VAMP ' s coiled-coiled domain. TI-VAMP mediates neurite outgrowth An assay was set up to measure the effect of transfection of NTs and TI-VAMP mutants on staurosporine-induced neurite outgrowth in PC 12 cells. First, w e show ed that when cells w ere electroporated with tw o plasmids. virtually all cells expressed both transgenes This was demonstrated by transfection with GFP-cellubrevin (GFP-Cb) alone. TeNT alone, or both. Co- transfection of TeNT with GFP-Cb resulted in total proteolysis of GFP-Cb. Second, the activity of transfected TeNT and BoNT E were demonstrated by complete proteolysis of endogenous synaptobrevin 2 and SNAP25 respectively. In a first set of experiments. PC 12 cells were transfected with GFP alone. GFP plus TeNT. GFP plus BoNT E or the Nter domain of TI-VAMP fused to GFP (GFP-Nter-TIVAMP. Figure 4B). The cells were then treated with staurosporine. and fixed after 24hours. Figure 5.A show s a representativ e field observed in each condition. Neurites from cells transfected with GFP or GFP plus TeNT w ere similar to neurites from untransfected cells. Neuπtes from cells transfected with GFP plus BoNT E or GFP-Nter-TIVAMP were fewer and shorter. The length of neurites and the number of neurites per cell were measured in each GFP-positiv e cell, in each condition. GFP plus TeNT had no effect on neurite number and length compared to GFP alone. BoNT E reduced by 45% the number of neurites longer than 20 μm and strongly increased the number of cells without neurites ( figure 5B.C). Expression of the Nter domain of TI-VAMP had an effect which was similar to that of BoNT E. GFP-Nter-TIVAMP reduced by 42% the number of neurites longer than 20μm and strongly increased the number of cells without neurites (figure 5B,C). The effects of GFP plus BoNT E and GFP-Nter-TIVAMP were statistically different from GFP alone with p= 0.02 " and 0.017 ( Student ' s t-test) respectively . The effects of BoNT E and GFP-Nter-TIVAMP were not additive, indicating that they act on the same exocytotic mechanism. In a different set of experiments, we measured the effect of GFP and GFP-Cyt- TIVAMP. GFP-Cyt-TIVAMP (neurites longer than 20μm: 50.2%+-'-0.25) had no effect on neurite length compared to GFP (neurites longer than 20 μm: 50.7%- ' -3.5 ). GFP-Cyt-TIVAMP had no effect on the number of neurites per cell. These results demonstrated that neurite outgrowth in staurosporine- treated cells is insensitive to TeNT but sensitive to BoNT E as in neurons. The fact that GFP-Nter-TIVAMP inhibited neurite outgrowth as strongly as BoNT E suggests that TI-VAMP plays a major role in neurite outgrowth. We then checked that GFP-Nter-TIVAMP expression did not have a deleterious effect. Figure 6 shows a gallery of double immunofluorescence experiments performed in GFP-Nter-TIVAMP transfected cells. We observed no effect on the localisation of syntaxin 1. a plasma membrane SNARE, syntaxin 6. a Golgi apparatus SNARE (figure 6). and SNAP25 when compared to untransfected or GFP-transfected cells. Synaptobrevin 2 appeared both in the perinuclear region and in the shorter neurites emerging from GFP- Nter-TIVAMP cells (figure 6 and compare to figure 1 ). These cells showed a low er lev el of expression of sy naptotagmin I Sy naptotagmin I was the vesicular marker which w as the most enriched in the tip of the neurites in untransfected cells (Figure 1 and 6) so our result may suggest that synaptotagmin I reached the neuritic tip by a TI-VAMP dependent pathway These results show ed that the Nter domain of TI-VAMP had a specific inhibitory effect on neurite outgrowth. We then tested the effect of GFP- ΔNter-TIVAMP expression and compared it w ith that of GFP-TIVAMP on neurite outgrowth. We observed the occurrence of unusually long neurites with an increased number of filopodia. Staining of actin filaments with fluorescent phalloidin show ed that the neuπtes of GFPIΔNter-TIVAMP-transfected cells showed cortical actin localisation similar to GFP-TIVAMP-transfected cells (Figure 7A ). The pattern of staining of tubulin. synaptobrevin 2. synaptotagmin 1. SN.AP25 and syntaxin 1 was the same in GFP- ΔNter-TIVAMP as in GFP-TIVAMP transfected and in untransfected cells. The effect of GFP- ΔNter-TIVAMP was quantified as in the case of GFP- ΔNter-TIVAMP. GFP- ΔNter-TIVAMP expression doubled the number of neurites longer than 30 μm and multiplied by 5 the number of neurites longer than 50 μm when compared to the expression of GFP-TIVAMP (Figure 7B). GFP-TIVAMP had no effect on neurite length and number per cell compared to GFP alone. We observed no effect of GFP- ΔNter-TIVAMP on the number of neurites per cell. We checked that GFP- ΔNter-TIVAMP formed more abundant SNARE complexes with endogenous SNAP25 by measuring the amount of SNAP25 and syntaxin 1 which was co-immunoprecipitated with GFP-ΔNter-TIVAMP. GFP-TIVAMP and GFP-Syb2. GFP- ΔNter-TIVAMP /SNAP25 complex was 2.5 times more abundant than GFP-TI VAMP/SNAP25. Accordingly, GFP- ΔNter-TIVAMP co-immunoprecipitated more syntaxin 1 than GFP-TIVAMP (Figure 7C). These results showed that a form of TI-VAMP. which had a higher SNARJΞ complex formation activity strongly, enhanced neurite outgrowth. Discussion Tetanus neurotoxm Insensitiv e-ø esicle Associated Vlembrane Protein ( TI- AMP DN A sequence SEQ ID N s aa s quence SEQ ID N 6 ) is a V SN ARE ( v esicle-associated soluble N-eth imaleide-sensitiv e fusion protein attachment receptor) w hich is know n to be inv olv ed in transport to the apical plasma membrane in epithelial cells The present inv ention reports for the first time that a N-termmal fragment ot a V AMP such as 1 I-VAMP can show biological functions in \ ι\o It is herein demonstrated that a fragment corresponding to the N-termmal domain which precedes the SNARE motif of TI-VAMP play s an inhibitory role on the activ ity of the VAMP TI-VAMP that SNAP25 is a target SNARE (t-SNARE) tor TI-VAMP in cells such as neuronal cells (1 e they form complexes in such cells) and that such a N-terminal fragment is capable of inhibiting the association of TI-VAMP w ith its target SNARE (SNAP25 in neuronal cells SNAP23 in epithelial cells ) The first 120 N-terminal aa fragment corresponds to SEQ ID V2 ( corresponding DNA sequence SEQ ID NT ) . the first 10 1 ones to SEQ ID V20 ( corresponding DNA sequence SEQ ID V I 9) Such N-termmal fragments are capable of inhibiting the membrane traffic activity of the cells into which they hav e been transfected they inhibit their fusion functions, and in a particular aspect, their exocytic functions Membrane traffic can be envisioned as a succession of vesicle budding, maturation v ectoπal transport, tethering docking and lipid bilayer fusion events Vesicular transport to and fusion at the plasma membrane i e exocytosis. is responsible for the release of soluble compounds such as neurotransmitters in the extracellular medium and for surface expression of plasma membrane proteins and hpids On a more mechanistic point of v iew such Nter fragments are herein shown to be capable of inhibiting the formation of complexes inv olv ing \ AMP and notabh complexes inv olv ing a V AMP such as TI-VAMP and at least one ot its t-SNARE (SNAP 25 SNAP23. syntaxin 1. syntaxm3) In fact such N-termmal fragments may inhibit any cell function which involves a tetanus neurotoxin-resistant pathway (TeNT- resistant) The overwhole resulting effect ot such N-termmal tragments on the properties ot said cells is to inhibit their membrane traffic activity t the transport ot components to its plasma membrane notabh through vesicular transport Conversely the TI-VAMP fragments which are deleted from their N-termmal domain (in so tar that their coiled coil motit activity is appropriately preserved / e said ΔNter tragments can still bind to at least one of their t-SNARE) are herein shown to exert stimulating effects on the membrane traffic activity ofthe cells into which they have been transfected they are capable of stimulating their fusion functions and in a particular aspect, their exocytic functions Conversely to Nter tragments such ΔNter fragments are herein shown to be capable of stimulating the formation of complexes involving VAMP, and notably complexes involving a VAMP such as TI-VAMP and at least one of its t-SNARE (SNAP 25. SNAP23. syntaxin 1 syntaxιn3) In fact, such ΔNter fragments may stimulate any cell function which involves a tetanus neurotoxin-resistant pathway (TeNT-resistant) The overwhole resulting effect of such ΔNter fragments on the properties of said cells is to inhibit their membrane traffic activity i e the transport of components to its plasma membrane, notably through vesicular transport The invention thus offers new means for controlling membrane traffic into a cells, and in particular for regulating fusion functions into a cell such as exocytic functions, and notably vesicular transports of components to the plasma membrane The means ofthe invention thus allow the regulation of very fundamental functions and properties of any cell that express a VAMP such as TI-VAMP In this respect, the skilled persons can envisage and perform from the teaching ofthe invention a very wide range of applications, and indeed any applications involving the regulation ot a traffic membrane and or of a TeNT-resistant pathway This notably includes the positiv e and negativ e control of neurite outgrowth and of cell motihty . this latter application being of special interest in the case ot metastasis-forming cells A particulai aspect of the inv ention indeed more precisely relates to neuπte outgrow th control the present inv ention show s tor the first time that SN ARE- mediated v esicular transport is essential to neurite outgrowth, l e to axonal and dendritic maturation and differentiation This is the first report of TIVAMP mediating neuπte outgrowth Elongation of axon and dendrites. so- called neurite outgrowth, is a crucial ev ent in neuronal differentiation and maturation . and thus in the dev elopment of he nerv ous sy stem Membrane traffic in dendrites is also of importance for s naptic plasticity and memory It is herein further demonstrated that o er-expression of a Nter fragment (such as SEQ ID V2 or V20) inhibits neurite outgrowth as strongly as botulmum neurotoxin (BoNT E), a neurotoxin which is known to abolish the expression of SNAP 25. the now -identified t-SNARE partner of TI-VAMP in cells such as neuronal cells It is also observed that such Nter fragments inhibit the formation of TI-VAMP'SNAP25 complexes in neuronal cells, and that the reverse effects are induced by ΔNter fragments of a VAMP such as TI-VAMP The above-described results indeed demonstrates that TI-VAMP - mediated v esicular transport is essential for neuπte outgrowth Expression of the N-terminal domain of TI-VAMP inhibits neuπte outgrowth as strongly as BoNT E, which abolishes the expression of SNAP25. a plasma membrane SNARE partner of TI-VAMP In the contrary , activ ation of neurite outgrowth and increased SNARE complex formation w ere observed when the N- termmus deletion mutant of TI-VAMP w as expressed in PC 12 cells A main conclusion from our work is that TI-VAMP is involv ed in neurite outgrowth in neuronal cells such as PC 12 cells Our findings that TI- V AMP interacts with SNAP25 in PC 12 cells and in the brain is consistent w ith the inv olv ement of SNAP25 in neurite outgrowth The TI-V AMP- dependent esicular transport mediating neurite outgrowth in PC 12 cells likely corresponds to the outgrowth of axons and dendrites in dev eloping neurons Indeed TI-V AMP concentrates in the leading edge ot axonal and dendritic growth cones of hippocampal neurons in pπmarv culture In support of this conclusion preliminary experiments hav e show n a decreased number ot neuπtes in v oung hippocampal neurons w hich w ere mιcro-ιn]ected w ith anti- TIV AMP antibodies Neuπte outgrowth may be also v ery activ e in differentiated neurons because it mav participate to post-sy naptic moφhological changes related to plasticity and learning A role for SN AP25 in neuronal plasticity and learning has been proposed Therefore, the TIVAMP and SNAP25 dependent vesicular transport mechanism descπbed here could also mediate activ ity -dependent exocy tosis involved in dendπte elongation and post-sy naptic receptor expression at the plasma membrane in mature neurons This could account for the distribution of TI-V AMP containing v esicles throughout the dendrites and of SN AP25 in the dendritic plasma membrane of mature neurons According to our present results, the proteic and lipidic map of TI-V AMP v esicular compartment is likely to identify factors, which are important for neuπte elongation both in developing and mature neurons The purification of TI-VAMP vesicular compartment allow s to determine which other proteins are involved in this pathway, particularly rab proteins that hav e been shown to play a role in neurite outgrowth W e found that the cytoplasmic domain of TI-VAMP. which comprises the N-terminal domain plus the R-SNARE motif, had no effect on neuπte outgrow th whereas the N-terminal domain alone strongly inhibited it This demonstrates that the full cy toplasmic domain is inactiv e in vivo The coiled- coiled domain of TI-VAMP bound more efficiently SNAP25 than the cy toplasmic domain by ov erlay assay Therefore our observ ations fav our a model in which the N-termmal domain of TI-VAMP acted as an intramolecular inhibitor of the R-SNARE motif prev enting it from forming SN ARE complexes Hence, identify ing the signal transduction pathw ay ( s ) and factors, able to activ ate TI-VAMP. w ill be of crucial importance to further understand how neurite outgrowth is controlled Finally , our finding that the N-terminal domain of TI-VAMP play s an important function in the control of neuπte outgrowth, suggests that this protein is a potential target of pharmacological agents that could modulate the activ ity of TI-VAMP by releasing the inhibition of this domain Such agents could be used to specifically activ ate TI-V AMP mediated exocytosis thus, stimulate neurite outgrowth Once identified, such drugs could be used in the treatment of ner e traumatisms such as spinal cord injury EXEMPLE 2 : SEQ ID N°2 or N°20 (Nter) inhibits the motilitv of tumor cells Cells such as tumor cells or the MDCK cell line ( Mardin Darby Canine Kidney ) can be used for transfection as abov e-described in example 1 so as to make them express a Nter polypeptide (M 1 to N 12^ of TI-VAMP. of the SEQ ID NT and V2 invention, a "deleted" polypeptide of the invention (M 102 to the end of human TI-VAMP. SEQ ID N°3 and V4). or the complete TIVAMP sequence (SEQ ID V5 and V6). These transfected cells can thus be placed into contact with a migration inductor such as a growth factor {e g HGF -Hepatocyte Growth Factor- for MKCK). and the differences in cell migration for each treatment can be observ ed v ideo-microscopy and/or confocal microscopy When appropriate, or desired, in o observ ations can be performed EXEMPLE 3: Appropriate formulations for drugs of the inv ention notably comprise tablet and injection solution, spray for chemical or peptidic products, and comprise hposome and v lrus for DN A products EXAMPLE 4: Expression of Nter and ΔNter in neu rons via electroporation or Adeno-associated v irus (Aav ) infection e expressed the amino-terminal domain and the form of TIVAMP deleted at its ammo-terminus in neurons to assay for the role of TIVAMP in the outgrowth of axons and dendrites We took adv antage of new techniques for transfectmg neurons, the electroporation of mouse embryonic brains, the infection of cortical-stπatal neurons in primary culture w ith recombinant adeno-associated v irus (Aavs) as well as the transfection mediated by calcium phosphate of primary hippocampal neurons to show that the expression of only the amino-terminal domain of TIVAMP blocks axonal and dendritic outgrow th, and alters the localization of the excitatory ammo acid carrier 1 (EAAC l ). a dendritic plasma membrane protein that is expressed early in neuronal development (Coco et al 199 " . Eur J Neurosci 9 1902- 1910 Verderio et. al. 1999. Cellular and Molecular Life Science 55 : 1448- 1462) Expression of the form of the protein deleted at its amino-terminus led to an increase in axonal length. Experimental procedures Antibodies and Clones Rabbit serums (TG 1 1 and TG 16. Galli et al 1998. Mol Biol Cell 9 1437- 1448 , Lafont et al. 1999 Proc. Natl Acad. Sci USA 96.3734-3738) directed against TIVAMP were purified by affinity chromatography in a column loaded with a 6xHιs-fusιon protein of the C-terminal SN ARE motif of TIVAMP (from residue E l 19 to K 188) For the micro-injection experiments the affinity -purified TG I 1 16 or control rabbit IgGs at nng ml ere dialy zed against PBS \ poh clonal antibodv directed against GFP w as generated in rabbit and affinity purified ov er recombinant GST-coupled GFP Mouse monoclonal ant odv directed against s naptobre in 2 ( clone 69 1 ) is obtainable from Max Planck Inst Goettingen FRG Antibodies against E AAC l and GluR l w ere used as described in Coco et al 199" Eur J Neurosci 9 1902- 1910 The cDNA ot human TIV AMP and the GFP-tusion constructs hav e been described in the abov e example 1 Electroporation of mouse embryonic brain Cortex were dissected out from mouse E 13 embry os in PBS 0 6 glucose (PBS-G) Plasmids (2ug ul) were co-mjected w ith 0 05% Fast-Green (Sigma St Louis, MO) using a glass capillary needle Electroporation was performed by 5 pulses (50 50ms) w ith a T-820 apparatus (BTX San Diego C A) using tw eezer electrodes (TR Tech Co Ltd Tokv o Japan) After electroporation cells were dissociated w ith PBS-G containing trv psin Dissociated cells were plated in matπgel-coated glass cov ershps in chemically defined medium as described (Mainguy et al 2000 Nat Biotechnol 18(7) 746-749) supplemented with 10% FCS After the indicated times cells were fixed with 4% PFA and either mounted with Vectashield-DAPI (4 ' ,6-dιamιdιno2- pheny hndole) (Vector Lab . Ine Burhngame. CA) for observation of direct GFP-signal or permeabihzed with 0 3% Triton X- 100 and processed for immunofluorescence according to standard techniques (Coco et al 1999. J Neurosci 19 9803-9812) Aav vectors construction, production, purification and titration rAAV-CMV-GFPTIVAMP, rAAV-CMVGFP-NtermTIVAMP. and rAAV- CMV-GFP-DTIV AVIP v ectors were respectiv eh obtained from the pCR3 1 GFPTIV AMP. pCR3 l GFPNtermTIVAMP pCR3 1 GFPDTIVAMP plasmids harboring the corresponding transgene and the pGG2 AAV plasmid The latter plasmid is deπv ed trom the pSUB20 l plasmid ( obtainable from ATCC ) w here the expression is driv en by hCM\ promoter and stabilized bv the SV40 late polv A and a chimeπc intron composed ot the 5 donor splice site of the first intron of the human beta globin gene ( hBB ) and the 3 ' acceptor splice site ot the intron of an immunoglobulin gene ( IgG) heav y chain v ariable region First GFPTIVAMP GFPNtermTIV AV1P GFPDTIVAMP sequences w ere PCR-amplified by using specific primers and the high fidelity pfu turbo polymerase ( Stratagene. La Jolla. CA ) and further digested by Nhel restriction enzy me at the 3 ' end These fragments were purified from agarose gel by using the geneclean kit (BIO 101 Vista. CA) according to the manufacturer's procedure Secondly , the pGG2 plasmid was cut by Nhel and EcoRV enzymes to add the PCR-amplified cDNAs The correct orientation of the inserted sequences were checked by DNA sequencing analysis and agarose gel electrophoresis Large scale production and purification of v ectors were performed by using the triple transfection of 293 cells (obtainable from ATCC). followed by CsCl density gradients purification, as previously described (Xiao 1998, J Cell Biol 143 KT7- 1086) The infectious particle concentration is determined by a variation of the procedure previously descπbed (Salvetti 1998. Hum Gene Ther 9(5) 695-706) Adeno-associated viral infection of neurons Cortical and stπatal neurons were prepared from rat E 16 embryos according to standard techniques in the art After dissociation neurons w ere plated in collagen-coated glass cov ershps in chemically defined medium as abov e Fiv e hours after plating cells w ere infected ov ernight w ith the described Aav s at a MOI of 100 in a final olume of 50μl The day after the Aa s w ere removed and cells were kept in regular medium for the indicated periods of time The direct GFP signal trom the Aav -encoded proteins could be detected 3 dav s after infection, how ever, to facilitate detection of the infected neurons for subsequent quantitation cells were fixed permeabihzed as described above and stained w ith anti-GFP antibodies Transfection of hippocampal neurons with calcium phosphate Calcium phosphate cry stals w ere prepared as descπbed in Maniatis et al 1982 ( Molecular Cloning a laboratory manual ( Cold Spring Harbor New York Cold Spπng Harbor Laboratory ot w hich content is herein incoφorated by reference) For transfection neurons w ere placed in medium conditioned by cortical astrocytes for at least 15 hours Calcium phosphate cr stals were left tor four hours, the cells w ere then w ashed accurately w ith Krebs-Ringer solution and transferred in their prev ious medium Antibody micro-injection in hippocampal neurons Cells used in micro-mjection experiments were seeded onto etched cov ershps to facilitate localization of injected cells During micro-injection experiments cells were maintained in Krebs-Ringer solution Micro-injections were performed in blind using a solution containing 1 mg/ ml of an affinity -purified rabbit antibody directed against TIVAMP or control IgGs Neurons were co- injected with 1 mg/ml dextran-FITC conjugated IgG (Sigma) to identify injected cells Micro-injections were performed using the Eppendorf 5242 micro-injector Commercial glass micro-capillaries w ith an outlet diameter of 0 5 -'- 0 2 mm (Femptotips. Eppendorf. Hamburg. FRG) were used Quantification of axonal and dendritic length in hippocampal neurons Randomly chosen fields were taken with a BioRad MRC- 1024 Confocal Microscope equipped w ith a LaserSharp 3 2 softw are Acquired images w ere processed and quantitatively analy zed with NIH Image 1 62 software from National Institute of Health, resulting in the analy sis of between 40 and 60 GFP-positiv e cells for each condition and for each independent experiment For immunocy tochemistry . neurons were permeabilized w ith 0 3% Triton X- 100 and processed for lmmunofluorescence as descπbed (Coco et al 1999. J Neurosci 19 9803-9812 ) Quantification of axonal length in cortico-stπatal neurons Randomly chosen fields w ere taken w ith a MicroMax CCD camera (Princeton Instruments ), resulting in the analy sis of betw een 10 and 50 ( in the electroporation experiments) or betw een 25 and 200 ( in the Aav experiments) GFP-positiv e cells, for each condition and for each independent experiment Quantification of axonal length w as done using the Metamoφh softw are (Princeton Instruments ) Double lmmunofluorescence with neuronal markers was performed in order to verif exclusiv ely quantification of neuronal cells The obtained data were analy zed for their statistical significance with Sigma Stat (SPSS. Ine ) Quantification of Nter-TI\ AMP-induced cell death After electroporation ot embryonic E 13 brains cells w ere dissociated and cultured in the absence or presence of 200uM zV AD ( Calbiochem. La Jolla. CA) to inhibit caspases thus apoptosis After 24h all the green-fluorescent neuronal and non-neuronal cells remaining were scored Results Expression of the amino-terminal domain of TIVAMP inhibits neuronal differentiation. To investigate the role of TIVAMP in neuronal differentiation w e expressed GFP and GFP fused to the amino-terminal domain of TIVAMP (GFP-Nter- TIVAMP). using a calcium phosphate-based transfection method, in E l 8 rat hippocampal neurons that were cultured in the presence of feeding glial cells (cf Figure 9 ) Neurons w ere transfected at 1 div or 4 div ( div = day s in v itro) and examined 24 hours later Dendritic function w as significantly altered in hippocampal neurons expressing GFP-Nter-TIVAMP because a reduced localization of the glutamate transporter EA AC l w as seen in the dendrites ot these cells compared w ith cells expressing only GFP ( Figure 9) Quanti fication ot dendrites positiv e tor EAAC l show ed that tar few er of them were fro neurons expressing GFP-Nter-TIVAMP than from neurons expressing only GFP (Figure 10 A) e did not observ e any effect on the localization of the AMPA receptor sub-unit GluR l ( Figure 9) This lack of effect show s that only a subset of transport pathw ay s are inhibited by the expression of GFP-Nter-TI\ AMP Interestingly dendrites of neurons expressing GFP-Nter-TIVAMP w ere few er in number and shorter than those neurons expressing GFP. after 2 div and 5 div , the strongest effect was after 2 div (Figure 10B. 10C) In comparison, the inhibitory effect of the expression of GFP-Nter-TIVAMP on axonal outgrowth appeared stronger than the effect on dendritic outgrowth, w hen only the lengths of the processes were compared (compare Figure 10B w ith 10D) The inv olv ement of TIVAMP in dendritic outgrowth w as further confirmed by the finding that micro-injection of an affinity -purified rabbit antibody directed against this protein into 1 div old hippocampal neurons from embry onic E l 8 rats but not of control rabbit IgGs resulted in a strong reduction of the number of dendrites (Figure 10E) Our observation that the inhibitory effect GFP-Nter-TIVAMP w as smaller when the transfection was performed in 4 div hippocampal neurons compared to 1 div neurons prompted us to study axonal and dendritic outgrowth in embryonic neurons of earlier stages For doing so, we electroporated intact embry onic brains from E 13 mice, then dissociated the cortices and stπata and cultured neurons and astrocy tes The cells were plated, cultured and observ ed after 1 to 3 div Using this approach, cells expressing GFP were abundant at both time points The dev elopment of neurons expressing GFP w as indistinguishable from that of non-transfected neurons and normal axonal and dendritic outgrowth w as observ ed How ev er, after 1 div . we could find only few cells expressing GFP-Nter-TIVAMP and after 3 div . almost none w ere v isible (Figure 1 1 A). Presumably expression of GFP- Nter-TIVAMP at early times during dev elopment blocked neuronal differentiation and rapidly induced neuronal cell death To test this presumption, w e treated the cells w ith benzy loxy carbony 1-Val-Ala-Asp- (O.Vle)-fiuoromethy lketone ( zVAD). a broad spectrum inhibitor of caspase (Polveπno and Patterson 199 " . J Biol. Chem 272( 1 1 ) 7013-7021 ). shortly after plating Cells treated w ith zVAD and expressing GFP-Nter-TIVAMP survived after 1 div but differentiation, as assessed by axonal and dendritic outgrowth, was severely impaired w hen compared w ith the corresponding cells expressing GFP alone (Figure 1 IA) Quantification of survival showed that zVAD reversed the pro-apoptotic effect induced by the expression of GFP-Nter-TIVAMP (Figure 1 IB). The neurons treated with zVAD and expressing GFP-Nter-TIVAMP surviving after 1 div showed a significant reduction in axonal length relative to cells expressing GFP alone (35 μm compared to 60 μm) (Figure 1 1 C ) and only 16% of their axons were longer than 50 μm compared w ith 62% in the case of GFP This result suggests that the deleterious effect of the expression of Nter-TIVAMP was due, at least in part, to inhibition of axonal and dendritic outgrowth The electroporation of intact brain, however, led to high level of expression of the transgenes and the apotototic effect could be due to nonspecific toxicity at high intracellular concentration, even though the control cells seemed normal. Therefore, we constructed recombinant Adeno-associated virus (Aavs) (Slack and Miller 1996, Curr. Opin. Neurobiol. 6(5): 576-583 : Du et al. 1996 Gene Ther. 3(3): 254-261) expressing GFP or GFP-Nter-TIVAMP and used them to infect cortico-striatal neurons. In this case also, the expression of GFP-Nter- TIVAMP resulted in strong inhibition of axonal and dendritic outgrowths, after 1. 2 and 3 div (Figure 1 I D). Staining w ith DAP1 showed that the DNA of cells expressing GFP-Nter-TIVAMP but not the DNA of cells expressing GFP w as condensed and fragmented This effect w as seen already in a majority of GFP-Nter-TIVAMP-expressing neurons after 1 div but affected v irtually all of the cells after 3 div (representati e cells are depicted in Figure 1 I D) Thus, the expression of GFP-Nter-TIVAMP mediated by the corresponding recombinant Aav resulted in neuronal cell death also in spite of the fact that infection w ith Aav induced a much low er lev el of expression than electroporation Consequently , this effect w as independent ot the method of transfection Altogether these results demonstrated that that TIV AMP is one o the proteins essential for both axonal and dendritic outgrow th A constitutively activ e form of TIVAMP enhances axon outgrowth. W e hav e prev iously found that the expression of a form of TIV AMP from which the amino-terminal domain has been deleted (GFP-ΔNter- TIVAMP) stimulated neurite outgrowth in PC 12 cells (see the above example 1) Because expression of GFP-Nter-TIVAMP blocked both dendritic and axonal outgrowths in neurons, w e asked w hether or not expression of GFP- ΔNter-TIVAMP had any effect on these processes Transfection of plasmids expressing GFP-ΔNter-TIVAMP by electroporation of intact E l 3 muπne brains greatly stimulated axonal outgrowth of neurons in primary culture (Figure 12. 13 A), and rat cortico-stπatal neurons infected with Aav s producing expression of GFP-ΔNter-TIVAMP also showed increased axonal outgrowth (Figure 12, 13B) None of these effects were seen in control cells upon expression of GFP or GFP-TIVAMP These stimulatory effects could be seen at 1 , 2, 3 or 6 div but the strongest effects w ere observed after 3 and 6 div in the case of Aav-treated neurons Most remarkably, expression of GFP-ΔNter- TIVAMP increased fourfold the percentage of axons longer than 300 um after 6 div (Figure 13B) The expression of full-length TIVAMP had no effect relativ e to the expression of GFP (Figures 13 A 13B) We did not observ e any significant effect of the expression of GFP-ΔNter-TIVAMP on dendritic length or on the number of dendrites per cell in any of the three models we hav e used. Remov al of the amino-terminal extension of TIVAMP produces a molecule of protein that has a structure t pical of brev ins. It w as possible that GFP-ΔNter-TIVAMP has lost important targeting information and behav es as sy naptobrevin 2 because it does not reach its site of normal function. If this w ere the case, these results w ould not provide insight into the function of TIV.AMP in axonal and dendritic outgrowth. Therefore, e studied the subcellular location of GFP-ΔNter-TIVAMP and sy naptobrevin 2 in cortico- striatal neurons 6 div after infection with Aav s. GFP-ΔNter-TIVAMP was found in cell bodies, dendrites. axon hillocks, all along the axon. and in varicosities (Figures 14A to 14E). We found that GFP-ΔNter-TIVAMP did not co-localize with synaptobrevin 2. Interestingly. GFP-ΔNter-TIVAMP densely localized at the leading edge of axons in the peripheral region of growth cones. a location devoid of synaptobrevin 2 (Figure 14E). as seen for the endogenous protein (Coco et al. 1999. J. Neurosci. 19: 9803-9812). Discussion As demonstrated in example 1. TIVAMP is one of the proteins essential for neurite outgrowth in PC 12 cells. In this example, it is directly confirmed that TIVAMP is essential for both dendritic and axonal outgrowth in neurons. Expression of the amino-terminal domain of TIVAMP inhibited axonal and dendritic outgrowth. Expression of a form of TIVAMP from which the amino-terminal domain has been deleted strongly enhanced axonal outgrowth in mouse cortical and striatal neurons but had no effect on dendritic outgrowth. The fact that the expression of these two proteins had opposite effects shows that the observed changes were not the result of the transfection itself but the identity of the proteins themselves. On the contrary, the amino-terminal domain of TI-VAMP seems to inhibit their capacity to form trans-SNARE complexes (example 1). Preliminary results show that a chimera consisting in the fusion of the amino- terminal domain of TIVAMP with synaptobrevin 2 leads to a v-SNARE with a reduced capacity to form complexes with syntaxin 4 and SNAP23 in fibroblasts. Altogether, our results suggest a model in which TIVAMP would be less active and more controlled v-SNAREs than brevins. The amino- terminal domain of TIVAMP is unlikely to contain targeting signals because the localization of ΔNter-TIVAMP is similar to that of the full length protein (Figures 12 and 14A- 14E ; Coco et al. 1999, see reference supra). Moreover, the stimulatory effect on axonal outgrowth resulting from expression of ΔNter- TIVAMP (Figures 13 A, 13B) is likely to be specific for TIVAMP because ΔNter-TIVAMP does not co-localize with synaptobrevin 2 (Figures 14A- 14E), in spite of the fact that it has a similar structure and high primary sequence similarity (Galli et al. 1998, Mol. Biol. Cell 9: 1437- 1448). Expression of Nter-TIVAMP inhibited neuronal differentiation (Figures 10A- 10E) and led to neuronal cell death (Figures l l .A- l lD). This effect cannot be due to a general deleterious effect of this peptide because we have shown that Nter-TIVAMP inhibits neurite outgrowth but does not lead to cell death in PC 12 cells (example 1 ). We found that apoptotic death occurred specifically in neurons and not in astrocytes. It was recently show n that theShc site of TrkB controls both neuronal surviv al and axonal outgrowth by activating the PI3-kinase and MEK signaling pathway s thus establishing a link between these two functions (At al et al. 2000. Neuron. 27(2 ): 265-2V ). Our results suggest that the apoptosis observed upon the expression of Nter-TIVAMP is a consequence of the inhibition of axonal and dendritic outgrowth. The fact that expression of Nter-TIVAMP blocked both axonal and dendritic outgrowths (Figures 10A- 10E and 1 1A- 1 1 D) indicates that both processes share common molecular mechanisms. The expression of Nter- TIVAMP in PC 12 cells (see example 1 ) and in the neurons examined in this study had no effect on the structure of the Golgi apparatus, as seen by syntaxin 6 immunolabeling, or in the intracellular distribution of synaptobrevin 2 and axonal and dendritic cytoskeletal components such as tau and MAP-2. so it is unlikely to induce pleiotropic effects on membrane traffic or other cellular functions. As suggested by its localization at the leading edge of both axonal and dendritic growth cones, vesicles the fusion of which is promoted by TIVAMP could transport proteins that are required both for axonal and dendritic outgrowth (Coco et al. 1999. see reference supra). The effect of Nter- TIVAMP on the dendritic expression of EAAC l (Figure 9), a protein that may- play a role in synaptogenesis (Coco et al. 1997. Eur. J. Neurosci. 9: 1902- 1910), but not on the expression of GluRl . a protein of the mature dendrite (Eshhar et al. 1993. Neurosci. 57(4): 943-964). suggests that TIVAMP could be inv olved in exocytosis of a very limited number of axonal and dendritic protins that are expressed at early stages of neuronal development. Our observation that expression of ΔNter-TIVAMP had no effect on dendritic outgrowth and that the expression of the Nter-TIVAMP had a higher efect on axons than on dendrites of hippocampal neurons (Figures 10A- 10E) can be explained if dendritic outgrowth normally functions at maximal rate and thus cannot be further activ ated, at least under our conditions of culture If this w ere so. the exocy tosis mediated by TIVAMP w ould be regulated differently in axons and dendrites This w ould be in agreement w ith se eral experiments show ing that dendritic and axonal outgrow ths are controlled by different signals (Prochiantz 1995. Neuron. 15 743-746) An alternativ e possibility is that TIV .AMP is primarily inv olv ed in axonal outgrowth and that dendritic outgrowth can proceed only when axonal outgrowth occurs normally . Indeed. our observations are reminiscent of recent w ork show ing that amyloid precursor protein first appears in axons and is then transported to dendrites by transcytosis. Both amy loid precursor protein and TIVAMP hav e been found in rafts, so the hypothesis that TIVAMP would follow neuronal transcytosis is a fashionable one It w ill now be important to characterize the proteins which control TIVAMP ' s mediated exocytosis. Specific axonal and dendritic factors are expected to regulate this pathw ay thus accounting for differential control of the growth rate of axons and dendrites in different ty pes of neurons. Such factors may include rab proteins (Huber et al 1995. Molecular & Cellular Biology 15 : 918-924), GTPases of the Rac and Rho families (Nakayama et al. 2000, J. Neurosci. 20( 14): 5329-5338) and kinesins (Terada and Hirokawa 2000, Curr. Opin. Neurobiol. 10(5): 566-573). It has been shown that TIVAMP is involved in several membrane trafficking steps in different cell types. It mediates apical exocytosis in epithelial cells, degranulation in mast cells, and participates in the EGF degradative pathway . This study establishes its intimate involvement in axonal and dendritic outgrowth. An appealing hypothesis could be that, among other cargo proteins, vesicles controlled by TIVAMP could contain hv drolases. These enzymes could be inv olved in the processing of membrane proteins and/or they could fulfill a function once they are secreted. Secretion of certain hv drolases may be important for elongation of axons and pathtinding because they would allow for specific penetration ot the extracellular medium by cleaving particular components of the basal lam a that would otherwise prevent elongation (McGuire and Seeds 1990 Neuron 4ι4) 633-642 Seeds et al 1990 Adv Exp Med Biol 265 169-P8) It this is the case TIVAV1P- containing vesicles would be routed to different target membranes depending on the cell type to endocytic structures in the case ot fibroblasts or to plasma membranes in the case of epithelial cells mast cells and differentiating neurons Such differences could also be correlated with different developmental stages Identification ofthe content ot these vesicles in neurons is expected to yield proteins that are important for axonal outgrowth and may suggest new strategies for the treatment ot severe traumatic nerve injuries

Claims: CLAIMS 1 . Isolated poly peptide. the sequence of w hich is selected from the group consisting of a sequence corresponding to SEQ ID V2. a sequence corresponding to SEQ ID V20. the sequences corresponding to any conservativ e fragment of SEQ ID NT. the sequences corresponding to any conserv ativ e fragment of SEQ ID V20. the sequences corresponding to any conservativ e v ariant of SEQ ID V2. the sequences corresponding to any conservativ e variant of SEQ ID V20. 2. Isolated polypeptide. the sequence of w hich is selected from the group consisting of the SEQ ID V6 sequence of which N-terminal domain has been deleted of at least one polypeptide according to claim 1. 3. Isolated polypeptide. the sequence of w hich is selected from the group consisting of SEQ ID V4. the sequences corresponding to any conservative variant of SEQ ID V4. and the sequences corresponding to any conservative fragment of SEQ ID V4. 4. Product selected from the group consisting of the monoclonal antibodies capable of binding to a polypeptide according to claim 1. and the Fab. F(ab ' ) 2 . CDR fragments thereof. 5. Product according to claim 4. characterized in that it is capable under physiological conditions of inhibiting at least one of the biological properties a polypeptide according to claim 1 can show . 6. Isolated polynucleotide. the sequence of which codes for a polypeptide according to claim 1 . Isolated poly nucleotide. the sequence of which is selected from the group consisting ot a sequence corresponding to SEQ ID NT a sequence corresponding to SEQ ID NT 9 the sequences corresponding to any conserv ativ e fragment ot SEQ ID N T . the sequences corresponding to any conserv ativ e v ariant of SEQ ID NT . the sequences corresponding to any conserv ativ e fragment of SEQ ID NT 9 the sequences corresponding to any conserv ativ e v aπant of SEQ ID V 19 8 Isolated poly nucleotide the sequence of w hich codes for a poly peptide according to any one of claims 2-3 9 Isolated poly nucleotide. the sequence of which is selected from the group consisting of the SEQ ID V5 sequences of which 5' domain has been deleted from at least one polynucleotide according to any one of claims 6-7 10 Isolated poly nucleotide. the sequence of which is selected from the group consisting of a sequence corresponding to SEQ ID V3 the sequences corresponding to any conserv ativ e fragment of SEQ ID V3. the sequences corresponding to any conservative v ariant of SEQ ID V3 1 1 Isolated polynucleotide, the sequence of which codes for a product according to any one of claims 4-5 12 Transfection v ector w hich comprises at least one polynucleotide according to claim 6 or 7 13 Adeno-associated v irus comprising at least one poly nucleotide according to claim 6 or 7 14 Transfection v ector, w hich comprises at least one poly nucleotide according to any one of claims 8- 1 1 15 Adeno-associated v irus, comprising at least one poly nucleotide according to any one of claims 8- 1 1 16 Genetically engineered cell comprising at least one element selected from the group consisting of the poh nucleotides according to claim 6. the polvnucleotides according to claim ". the transfection v ectors according to claim 12. the adeno-associated v irus according to claim 13 17. Genetically engineered cell comprising at least one element selected from the group consisting of the poh nucleotides according to claims 8-1 1 , the transfection v ectors according to claim 14. the adeno-associated virus according to claim 15 18. Pair of oligonucleotides characterized in that it is capable under standard PCR conditions to amplify at least one poly nucleotide according to claim 6 or 7. 19. Pair of oligonucleotides of w hich respectiv e sequences correspond to SEQ ID NT 1 and SEQ ID NT 2 20. Pair of oligonucleotides characterized in that it is capable under standard PCR conditions to amplify at least one poly nucleotide according to any one of claims 8- 10 21. Pair of oligonucleotides of w hich respectiv e sequences correspond to SEQ ID NT 5 and SEQ ID NT 6 22 Isolated poly nucleotide obtainable by using on a poly nucleotide population at least one pair of oligonucleotides according to claim 18 or 19 23 Isolated poly nucleotide obtainable by using on a poly nucleotide population at least one pair of oligonucleotides according to claim 20 or 2 1 24 Pharmaceutical composition comprising at least one product selected from the group consisting of the poly peptides according to claim 1. the poh nucleotides according to claims 6. ~ . 22. the transfection v ectors according to claim 12. the adeno-associated v irus according to claim 13. and the cells according to claim 16 25. Pharmaceutical composition comprising at least one product selected from the group consisting of the polypeptides according to claims 2-3. the polvnucleotides according to claims 8- 1 1. 23. the transfection vectors according to claim 14. the adeno-associated v irus according to claim 15. and the cells according to claim 17 26. Method for identify ing a pharmaceutical agent capable of stimulating a cell function selected from the group consisting of the cell functions involving a membrane traffic, the cell functions involving a TeNT-resistant pathway, the cell functions involving the formation of complexes with TI-VAMP, the cell functions involving at least one TI-VAMP, the cell functions involving a fusion, or an exocytic event, the cell functions involved in neurite outgrowth. in neuronal maturation, in neuronal differentiation, in neuronal or dendritic v iability , in memory abilility . and in learning capacity , characterized in that it comprises at least one step chosen the group consisting of " - the identification of an agent that is capable under physiological conditions of blocking or diminishing the inhibition effect that is obser ed w hen the cy toplasm of a cell is placed into contact with at least one product selected from the group consisting of the polypeptides according to claim 1 the poh nucleotides according to claim 6 " 22 the transfection v ectors according to claim 12 the adeno-associated v irus according to laim 13 the cells according to claim 16 under conditions appropπate to ceil membrane trafficking the identi fication of an agent that is capable under phvsiological conditions to compete w ith a product according to any one of claims 4-5 tor binding to at least one poly peptide according to claim 1 the identification of an agent that is capable under ph siological conditions of stimulating the formation of complexes involv ing at least one polypeptide according to any one of claims 2-3. and at least one t-SNARE the identification of an agent that is capable under phy siological conditions of exerting an additional or sy nergic effect on the cell function observed when the cytoplasm of a cell is placed under conditions appropriate to cell membrane trafficking into contact w ith at least one product selected trom the group consisting of the poly peptides according to claims 2-3. the products according to claims 4, 5. the poh nucleotides according to claims 8- 1 1. 23. the transfection vectors according to claim 14, the adeno-associated virus according to claim 15. the cells according to claim 17. - the identification of an agent that is capable under physiological conditions of prev enting the formation of complexes between compounds which comprise at least one polypeptide according to claim 1. or of disrupting or destabilizing such complexes 2 7 Method for identify ing a pharmaceutical agent capable of inhibiting a cell function selected from the group consisting of the cell functions inv olv ing a membrane traffic, the cell functions involv ing a TeNT-resistant pathway , the cell functions inv olv ing the formation of complexes w ith TI-VAMP, the cell functions inv olv ing at least one TI-V AMP the cell functions inv olv ing a fusion, or an exocy tic ev ent, the cell functions inv olv ed in cell motihty the cell functions in olv ed in the formation of metastasis characterized in that it comprises at least one step selected from the group consisting of - the identification of an agent that is capable under phy siological conditions of stimulating the inhibition eftect observ ed w hen the cv toplasm of a cell is placed under conditions appropπate to cell membrane trafficking into contact w ith r least one product selected from the group consisting of the polv peptides according to claim 1 the poh nucleotides according to claim 6 " 22 the transfection v ectors according to claim 12. the adeno-associated v irus according to claim 13. the cells according to claim 16 - the identification of an agent that is capable under physiological conditions of inhibiting the formation of complexes involving at least one polypeptide according to any one of claims 2-3 and at least one t-SN ARE. the identification of an agent that is capable under physiological conditions of exerting an inhibitor, effect on a cell function that is observ ed when the cytoplasm of a cell is placed into contact, under conditions appropriate to cell membrane trafficking, with at least one product selected from the group consisting of the polypeptides according to claims 2-3. the products according to claims 4-5, the polvnucleotides according to claims 8- 1 1 , 23, the transfection vectors according to claim 14, the adeno-associated virus according to claim 15, the cells according to claim 17 - the identification of an agent that is capable under physiological conditions to ly se a product according to claim 5, the identification of an agent that is capable under physiological conditions of stimulating the formation of complexes betw een compounds w hich comprise at least one polv peptide according to claim 1. or of stabilizing such complexes or of preventing the disruption of such complexes 28 The use ot at least one product selected from the group consisting of the poly peptides according to claim 1 the poh nucleotides according to claim 6 22 the transfection v ectors according to claim 12. the adeno-associated v irus according to claim 13 the cells according to claim 16. the pharmaceutical agents obtainable by the method of claim 2 " for the production of a drug intended for at least one effect selected from the group consisting of inhibiting a cell membrane traffic, inhibiting a vesicular transport, inhibiting a function involving a TeNT-resistant pathway , inhibiting a function involving at least one TI-VAMP. inhibiting the formation of complexes inv olv ing at least one TI-VAMP and at least one t-SNARE, inhibiting a cell motihty. inhibiting the motihty of cells susceptible of forming metastasis 29 The use of at least one product selected from the group consisting of the polypeptides according to any ones of claims 2-3 the products according to any one of claims 4-5. the poh nucleotides according to any one of claims 8- 1 1. 23. the transfection v ectors according to claim 14. the adeno-associated virus according to claim 15, the cells according to claim 17. the pharmaceutical agents obtainable by the method of claim 26, for the production of a drug intended for at least one effect selected from the group consisting of stimulating a cell membrane traffic, stimulating a vesicular transport, stimulating a function involving a TeNT-resistant pathway . stimulating a function inv olving at least one TI-VAMP, stimulating the formation of complexes involving at least one TI-VAMP and at least one t- SNARE. stimulating axonal and/or dendritic outgrowth, stimulating neuronal maturation, stimulating neuronal differentiation, prev enting or decreasing neuronal apoptosis. stimulating memory and/or learning capacity, curing and or palliating and/or prev enting spinal cord trauma, curing and'or palliating and or prev enting neuro-degenerativ e disorders curing and or palliating and or prev enting sclerosis 30 Vlethod tor the diagnostic an undesired state and or for assessing the efficiency ot a medical treatment and or tor assessing the ev olution ot an undesired state characterized in that it comprises at least one step selected from the group consisting of - detecting in a biological sample that a product selected trom the group consisting of the poly peptides according to claims 2-3 the products according to claims 4-5 the polvnucleotides according to claims 8- 1 1 23 the transfection vectors according to claim 14 the adeno-associated v irus according to claim 15. the cells according to claim 17, is present in a quantity or concentration significantly different from the standard lev el, or - detecting in a biological sample a level of expression for a polypeptide according to claim 1 significantly different from the standard lev el, or - detecting in a biological sample that the quantity or concentration of complexes involv ing compounds which comprise at least one polypeptide according to claim 1. is significantly different from the standard lev el 3 1 A method for identifying a compound capable of acting as a biological effector of TI-VAMP. characterized that it comprises the detection of a compound which is capable under physiological conditions of binding to a polypeptide according to claim 1 , - the detection of a compound which is capable under physiological conditions of diminishing the inhibition effect that is observed when the cytoplasm of a cell expressing TI-VAMP is placed into contact w ith at least one product selected from the group consisting of the polypeptides according to claim 1. the polv nucleotides according to claim 6. 7. 22. the transfection vectors according to claim 12. the adeno-associated v irus according to claim 13 the cells according to claim 16. under conditions appropriate to cell membrane trafficking. - the detection of a compound w hich is capable under physiological conditions of exerting an additional or sy nergic effect on the cell function that is observed w hen the cy toplasm of a cell expressing TI-VAMP is placed into contact w ith at least one product selected from the group consisting of the poly peptides according to claims 2- 3. the products according to claims 4-5 the poh nucleotides according to claims 8- 1 1. 23. the transfection v ectors according to claim 14. the adeno-associated v irus according to claim 15. the cells according to claim l 7 , under conditions appropriate to cell membrane trafficking

Inventors: GALLI THIERRY, LOUVARD DANIEL, MARTINEZ SONIA, GALLI, THIERRY, LOUVARD, DANIEL, MARTINEZ, SONIA
Applicants: CENTRE NAT RECH SCIENT, GALLI THIERRY, INST CURIE, LOUVARD DANIEL, MARTINEZ SONIA, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (C.N.R.S.), GALLI, THIERRY, INSTITUT CURIE, LOUVARD, DANIEL, MARTINEZ, SONIA
Application year: 2001
Main classification: C12N15
IPC codes: A61K38, C07K14, C12N15